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ABSTRACT
In utero and Postnatal Oxycodone Exposure: Implications for
Intergenerational Effects
Katherine E. Odegaard, Ph.D.
University of Nebraska Medical Center, 2021
Supervisor: Sowmya V. Yelamanchili, Ph.D.
Prescription opioid abuse during and after pregnancy is a rising public health
concern. Adding a layer of complexity is the role of heredity in the overall development of
these exposed offspring. The present work uses a preclinical rat model mimicking
oxycodone (oxy) exposure in utero (IUO) and postnatally (PNO) to investigate
comparative and intergenerational effects in the two different exposure groups.
To understand the direct effects of IUO and PNO exposure on the F1 generation,
we employed a systems biology approach encompassing proton magnetic resonance
spectroscopy (1H-MRS), electrophysiology RNA-sequencing, and pain assessment to
elucidate molecular and behavioral changes in these offspring. 1H-MRS studies revealed
significant changes in brain metabolites that were corroborated with changes in synaptic
currents. RNA-sequencing of the prefrontal cortex further revealed alterations in the
expression of key genes associated with synaptic transmission, neurodevelopment, mood
disorders, and addiction. Von Frey testing showed lower pain thresholds in both oxyexposed groups. Further, because addictive drugs produce significant and persistent
changes in the synapse, we investigated the synaptic vesicle (SV) contents of the PNO
and IUO groups. To that end, we found that the expression levels of key SV proteins
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associated with functional pathways and neurological disease were altered in oxyexposed groups.
While our earlier studies characterized the effects PNO and IUO exposure have
on the F1 generation, we next sought to compare the overall development between F1
offspring and their progeny, the F2 generation. We observed significant differences in
phenotypic attributes of both generations in each treatment group, and RNA-sequencing
of the nucleus accumbens revealed alterations in the expression of key synaptic genes in
both generations. Post-validation of these genes using RT-PCR highlighted the differential
expression of several neuropeptides associated with the hypocretin system, a system
recently implicated in addiction. Further, behavior studies revealed anxiety-like behaviors
and social deficits in both treatment groups that persisted into the F2 generation.
Collectively, our studies reveal a new line of investigation on the potential risks
associated with oxy use during and after pregnancy, specifically the disruption of
neurodevelopment and the intergenerational impact on behavior.
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INTRODUCTION
Substance Use and Abuse
Substance use in the form of alcohol and plant-derived drugs has existed for
thousands of years. Psychoactive drugs as well as hallucinogens were used in spiritual
and religious rituals of many early cultures in order to rid the body of evil spirits.1 Presently,
many people view substance use, or drug use, as bad, and label the drug as the inherent
evil of addiction. It is important to realize, however, that drugs are not inherently evil, and
rather their use determines their utility and impact. The term drug abuse is defined as “the
use of a substance in a manner, amount, or situation such that the drug use causes
problems or greatly increases the chance of problems occurring,” and it may lead to
dependence. Drug dependence refers to the state in which the individual uses the drug
so frequently and consistently that it would be difficult for the person to get along without
the drug; dependence refers to the physical dependence on a substance, which can be
characterized by phases of withdrawal and tolerance.1 This dependence can ultimately
lead to what we commonly term as addiction, which is characterized by a change in
behavior due to biochemical changes that take place within the neural circuitry of the brain,
leading to substance use disorder (SUD).

Substances of Abuse
Substances of abuse include legal and illegal substances that possess varying
mechanisms of action and impacts in the brain. These substances are capable of inducing
plastic changes in the brain that impact overall brain function and contribute to substance
use disorders.2 The three predominant classes of commonly misused or abused
substances are psychostimulants, depressants, and opioids.
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Psychostimulants
Psychostimulants, which include methamphetamine, cocaine, and nicotine, are the
most widely abused class of drugs. Psychostimulants increase stress and hyperactivity in
the central nervous system (CNS) by enhancing or mimicking catecholamine
neurotransmitters such as dopamine,3,4 contributing to the brain’s susceptibility to
senescence, damage, and dysregulated plasticity.5,6 Some psychostimulants are also
capable of acting on serotonin receptors to induce hallucinogenic and psychogenic
effects.7 Cocaine and methamphetamine both operate pharmacologically through
presynaptic monoamine receptors and are highly addictive drugs that can cause severe
withdrawal symptoms.8,9 The mechanism of addiction of these two substances likely lies
in synaptic plasticity and memory pathways.10 Nicotine, however, acts as an agonist to the
nicotinic acetylcholine receptors on dopaminergic neurons to exert its effects on the
dopaminergic reward system.11
Depressants
Depressants like alcohol and marijuana are named for their ability to impair and
depress both behavioral and mechanical functions. Alcohol, similar to nicotine in legality,
is one of the most abused drugs in the world. Δ9-tetrahydrocannabinol (THC), the primary
psychoactive component in marijuana, has also received significant attention recently due
to its increasing social and legal acceptance worldwide. While both of these substances
are canonically described as depressants, their methods of action in the brain are very
different. Alcohol use affects GABA receptors, glutamate receptors, NMDA receptors,
nicotinic acetylcholine receptors, and serotonin receptors,12,13 and acute alcohol use has
been shown to increase extracellular dopamine release and alter synaptic plasticity.14
THC, on the other hand, binds to the cannabinoid 1 receptor (CB1), mediating dopamine
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release in the striatum and altering neural components of salience processing and the
mesolimbic pathway.15
Opioids
Although typically prescribed for pain management, opioids are known for their
addictive potential and recent rise in abuse.16,17 Prescription opioids include Vicodin
(hydrocodone), Oxycontin and Percocet (oxycodone), Opana (oxymorphone), Kadian and
Avinza (morphine), codeine, and fentanyl. Full or partial opioid agonists such as
methadone and buprenorphine, respectively, are also commonly prescribed for pain or the
treatment of opioid dependence.18 In addition to prescription opioids, illegal opioids such
as heroin and opium are also widely abused.19-21 The common factor of all opioids,
regardless of legality, is their action on the opioid receptors that are widely dispersed in
the brain and spinal cord, allowing for complex addiction pharmacodynamics.22

Reward Circuitry of the Brain
Addictive drugs, such as opioids, psychostimulants, and depressants, enhance the
functioning of the reward circuitry of the brain, leading to the “high” sought by drug users. 23
First discovered by Olds and Milner at McGill University in 1954,24 the reward circuitry
consists of dopaminergic neurons in the ventral tegmental area (VTA) projecting to the
nucleus accumbens (NAc), prefrontal cortex (PFC), amygdala, and hippocampus (Figure
1). The NAc also receives glutamatergic innervation from the PFC, amygdala, and
hippocampus.25 Although the mechanisms of action are dependent on drug type, the initial
common action of all addictive drugs is the increase in dopaminergic signaling from the
VTA to the NAc, creating a strong reinforcement that may lead to maladaptive behaviors
and, in some cases, compulsive consumption in the user.26 The hypothesis of
reinforcement stems from the measure of extracellular dopamine in the NAc 27 and in the
observation that reinforcement in mice and rats is driven by the electrical activation of the
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medial forebrain bundle, which includes axons from the VTA to the NAc, 24 or the
optogenetic excitation of VTA dopamine neurons.26,28-30 The dopamine neurons involved
in this reward circuitry may be responsible for the reward prediction error that drives
associative learning.31 Within this circuitry, excessive dopamine signaling resulting from
drug use may modulate gene expression and alter synaptic function circuit activity over
time, resulting in the maladaptive behaviors associated with addiction.
Along with dopamine, several other neurotransmitters and neuromodulators work
to regulate the specific circuitry associated with addiction. Dopamine, opioid peptides,
GABA, glutamate, serotonin, acetylcholine, and endocannabinoid systems all have roles
in the reward pathway at the level of either the VTA or NAc. In a healthy brain, the reward
circuit is balanced with proper inhibitory control, decision making, and normal functioning
of reward, motivation, stress, and memory circuits. These circuits also interact with other
brain regions involved in mood regulation, such as the amygdala and hypothalamus.
Drugs of abuse manipulate these circuits through the use of neurotransmitters, including
dopamine, enkephalins, glutamate, GABA, norepinephrine, corticotropin-releasing factor,
dynorphin, neuropeptide Y, and endocannabinoids.32 Excess of these neurotransmitters,
particularly dopamine and glutamate, can contribute to neuroinflammation by binding to
the receptors expressed on microglia and astrocytes to amplify inflammatory signaling
through the release of cytokines and chemokines.33 Inflammation and gliosis, the
proliferation of glial cells, are pathological features of SUDs.34,35 SUDs also affect the
release of synaptic vesicles (SVs), which are largely responsible for neurotransmitter
release; cocaine36 and alcohol37 use disorders have highlighted alterations in the
expression of proteins essential for SV release, thereby affecting synaptic transmission.
These drug-induced changes to the reward pathway highlight the complexity of
downstream effects of SUDs. The following sections provide more information on the roles
of individual reward brain regions in SUDs.
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Figure 1. Simplified diagram of the major connections and areas involved in the reward
circuitry of the brain. Created using Biorender.com.
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Ventral Tegmental Area
The VTA is a region of the brain located near the midline of the midbrain floor that
is largely composed of dopamine-producing neurons. With their diffuse connections to
regions such as the NAc, amygdala, PFC, and basal ganglia, these dopamine neurons
have critical roles in reward- and goal-directed behaviors.38 Drugs of abuse activate these
VTA dopamine neurons, resulting in the release of dopamine that affects many different
cell populations throughout the VTA circuitry and subsequently regulates motivated
behaviors.39 The activity of these dopamine neurons is regulated by inputs from other brain
regions as well as by local GABA- and glutamate-releasing neurons in the VTA. These
GABA and glutamate neurons also have long-range projections to many of the brain
structures that are innervated by the VTA dopamine neurons.38 Specifically within the VTA,
glutamate40 and GABA41 have roles in binge and intoxication, and corticotropin-releasing
factor has a role in withdrawal and negative affect.42
Nucleus Accumbens
The NAc is located in the rostral part of the basal forebrain, just below the corpus
striatum. Also called the ventral striatum, the NAc is referred to as the pleasure center of
the brain, playing roles in motivation and cognitive processing of aversion. 39 The NAc
receives input from VTA dopamine neurons, and the NAc has further innervations with the
PFC, amygdala, hippocampus, and the basal ganglia. The NAc is composed of two
regions: the core and the shell. While the NAc core is primarily responsible for the
evaluation of reward and initializing reward-related motor action, the NAc shell is
responsible for reward prediction and reward learning.43 Transcerebral brain microdialysis
studies have shown that dopamine transmission in the NAc was stimulated by
psychostimulants, analgesics, and depressants.44 Interestingly, NAc shell neurons make
strong GABAergic connections with VTA dopamine neurons, allowing the NAc shell
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neurons to inhibit VTA dopamine neuron firing.45 Repetitive stimulation of dopamine
transmission in the NAc through continued substance use causes stimuli associated with
drug reward to acquire excessive incentive value and facilitate behaviors necessary for
drug taking and SUDs.44 The motivation to take more of a drug is further driven by the
glutamatergic projections from the PFC, hippocampus, and amygdala to the striatal
projections that increase dopamine signaling and release in the NAc.46 Dynorphin
signaling in the NAc has also been shown to have a role during withdrawal and negative
affect.47
Prefrontal Cortex
The PFC is the section of frontal cortex at the anterior of the brain that is involved
in self-awareness, complex planning, problem solving, learning and memory, executive
functions, decision making, and social behavior.48 The PFC is largely involved in
controlling intense emotions and impulses and uses working memory to guide behavior
and attention.39 While it has several connections with brain regions associated with
attention, action, and cognition, its reciprocal connections with the VTA and amygdala are
important in the behavioral reactions to chronic drug abuse. Plastic changes within the
brain associated with drug- or cue-induced reinstatement after extinction have been linked
to glutamatergic pathways extending from the PFC to the NAc and GABAergic pathways
from the NAc to the basal ganglia.49,50
Amygdala
The amygdala is a critical region of the limbic system that plays a key role in
processing emotions, learning, memory, reward, attention, and arousal. The amygdala
aids in the learning of the association between drug use and the subsequent “high”
resulting from dopamine release. Inactivation of the amygdala prevents reinstatement
cues during self-administration, and chronic exposure to drugs disrupts the projections
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spanning from the amygdala to the PFC.39 Dopamine exerts neuromodulatory control over
excitatory and inhibitory transmission between the amygdala and the PFC; specifically,
dopamine D1 receptor activity suppresses amygdala-evoked excitatory response in PFC
neurons, and dopamine D2 attenuates amygdala-evoked inhibitory responses.
Corticotropin-releasing factor,51 neuropeptide Y,52 and endocannabinoids53 in the
amygdala have also been implicated in withdrawal, and glutamate signaling54 in the
amygdala has been associated with drug craving.
Hippocampus
As a major structure in the limbic system, the hippocampus plays an important role
in memory formation and novel object recognition. Hippocampal learning, memory, and
plasticity have been shown to be heavily involved in the development and maintenance of
addiction.55 The dentate gyrus of the hippocampus contains neuronal progenitor cells that
generate new neurons and contribute to neurogenesis.39 Interestingly, most substances
of abuse have been shown to suppress hippocampal neurogenesis.56,57 Substance use
has also been shown to affect hippocampal long-term potentiation (LTP)58-61 and longterm depression (LTD).39,62 Additionally, the hippocampus receives dopamine input from
the VTA, which helps modulate hippocampal plasticity as well as learning and memory.
Glutamate signaling in the hippocampus has also been linked to drug craving.63
Hypothalamus
The hypothalamus integrates brain function with the body’s physiological needs
and is thought to coordinate motivation with physiological demands.64 Specifically, the
hypothalamus’s role in the hypothalamic-pituitary-adrenocortical axis (HPA) has been
investigated in the context of addiction. The HPA has an essential role in normal
physiological processes and in adaptation to stress, processes that are disrupted with
drug abuse.65 In response to stress and chronic substance abuse, levels of corticotropin-

9

releasing factor, which is released primarily by the thalamus and hypothalamus, increase,
stimulating the secretion of adrenocorticotropic hormone by the anterior pituitary.64 Of
particular interest in the hypothalamus’s role in the reward system are the hypocretincontaining neurons. These neurons have wide projections throughout the brain, including
projections to the midbrain and the VTA. As chronic drug use and stress levels increase,
more corticotropin-releasing factor is produced, activating hypocretin neurons. Sustained
activation of these hypocretin neurons recruits N-methyl-D-aspartate (NMDA) receptors
to VTA synapses, resulting in an increased response to glutamatergic neurons.66 These
NMDA receptors are also necessary for the induction of LTP and the promotion of burst
firing in dopamine neurons, which may increase the dopamine output in regions of the
VTA. Thus, the increased glutamatergic signaling by hypocretin neurons in the VTA may
increase dopamine output and enhance the reinforcing properties of substances of
abuse.67

Genetics and Epigenetics of Substance Use
As SUD is considered a chronic relapsing brain disease, it is crucial to understand
the underlying causes of this disease. Mounting evidence suggests that SUDs run in
families;68,69 twin, adoption, and sibling studies implicate genetic factors are involved in
the heritability of substance abuse.70 Several human genome-wide association studies
have identified loci and genes associated with substance use disorders,69,71,72 revealing
heritability estimates of substance use between 0.39 and 0.72.71 Environmental factors,
such as stress and socioeconomic status, also shape an individual’s susceptibility to
addiction.73 Studies have shown that gene-environment interactions can influence
behavioral phenotypes. For example, variations in the 5-HTTLPR promoter of the
serotonin transporter SLC6A4 gene, which codes for the serotonin transporter (a target
for cocaine),74 have been shown to be moderated by parenting or mentoring relationships,
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suggesting that environmental conditions can regulate genetic predispositions such as
vulnerability for SUDs.75 However, the inheritance of substance abuse cannot be
explained entirely through genetic mechanisms alone; the interactions between genotype
and environmental factors point toward a critical role of epigenetics in the response to
substances of abuse and the development of SUDs.76
Epigenetics refers to the alteration of gene expression without changes to DNA
sequence.77,78 Epigenetic mechanisms provide a dynamic and heritable means of altering
gene expression in response to environmental factors. Briefly, genes are composed of
nucleotide base pairs in the DNA that are unique to that gene. Base pairing occurs
between cytosine and guanine and between adenine and thymine. Cytosines followed by
guanines in the DNA sequence are called CpGs, and they can be modified by DNA
methyltransferases to add a methyl group, effectively reducing the accessibility of the gene
and “silencing” its expression.79 Methylated DNA interferes with the binding of
transcriptional activators or binds to other proteins to collectively form a complex that
further represses DNA accessibility.80 Demethylation of DNA, either through DNA
methyltransferase malfunction or enzymatic reaction, “reopen” accessibility to the
previously suppressed gene.79 Specific instances of DNA methylation associated with
substances of abuse focus largely on epigenetic changes in the NAc. One well-established
marker of repeated drug exposure is the increase in expression of the transcription factor
protein ΔFosB in the NAc.81 Acute or chronic cocaine administration has been shown to
decrease methylation at the fosB promoter in the NAc of rodents, which co-occurs with
increases in fosB mRNA expression.82 Overexpression of ΔFosB has been correlated with
increased sensitivity to the behavioral effects of substances of abuse and increased drugseeking behavior, suggesting that ΔFosB may be a critical component in the long-term
neural and behavioral plasticity underlying SUDs.83
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In addition to DNA methylation, modification to histones, proteins that associate
with DNA in the nucleus and condense it into chromatin, can also contribute to epigenetic
changes. Histones are comprised of two copies of each of four histone proteins, H2A,
H2B, H3, and H4, and modifications to the amino acid residues of these proteins can
remodel the chromatin, allowing the DNA to be more tightly (heterochromatin) or loosely
(euchromatin) packaged. The addition of acetyl groups to histone proteins allows the
chromatin to be less condensed and more easily accessed. Acetylation of H3 and H4
subunits in the NAc following drug exposure suggests that many genes in the NAc may
be primed for transcription.84 Indeed, H4 acetylation in this region contributed to the
increased expression of fosB in rodents.85 In contrast, methylation of histone proteins can
result in either transcriptional activation or repression, depending on which histone residue
is affected.79 For example, methylation of H3 Lysine 9 has been correlated with
transcriptional repression. Interestingly, G9a, a histone methyltransferase that methylates
H3 Lysine 9, is decreased in the NAc following both chronic cocaine and opiate
administration.86,87 G9a appears to oppose ΔFosB expression,86,87 and ΔFosB represses
G9a expression, creating a feedback loop that perpetuates its own expression through
disinhibition. Importantly, postmortem NAc brain tissue of human cocaine users showed
decreases in G9a expression88 and increases in ΔFosB expression.89 These modifications
to the accessibility of DNA can be inherited by future generations, potentially affecting the
susceptibility of these generations to SUDs.

Generational Inheritance of Substance Use
Because epigenetic inheritance can result from modifications passed down from
the mother, father, or both, resulting in either maternal, paternal, or parental epigenetic
inheritance, respectively, it is important to define the type of generational inheritance:
multigenerational,

intergenerational,

or

transgenerational.90,91

Transgenerational
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inheritance is the germ-line-mediated inheritance of epigenetic information between
generations in the absence of direct environmental influences that lead to phenotypic
variation, meaning a true transgenerational study must include at least one generation
that receives no direct exposure to the stimulus.92 While the definition of transgenerational
inheritance is fairly straightforward, defining inter- and multi-generational inheritance is
slightly more difficult.90 If the F0 drug use occurs in males or in females prior to pregnancy,
the germ cells, which will become the F1 generation, are exposed to the drug. Because
both the F0 and the F1 generations are directly exposed to the drug, their inheritance
pattern is considered intergenerational. In this scenario, the F2 generation would be the
first generation not exposed to the drug, resulting in transgenerational inheritance.
Alternatively, if the F0 female is exposed to the drug during pregnancy or postpartum, the
somatic and germ cells of the F1 offspring receive direct exposure to the drug in utero or
postpartum via the breastmilk.93 Since the F1 germ cells are exposed to the drug, and the
F2 offspring originate from those germ cells, the first generation without direct exposure
to the drug is F3. In these cases, a study spanning from F0 to F3 would be considered
transgenerational, as F3 is the first generation without direct exposure; a study spanning
from F0 to F2 would be considered multigenerational.
Multigenerational inheritance is the coincident direct exposure of multiple
generations to an environmental factor promoting alterations in the multiple generations
exposed.94 Therefore, in the scenario of drug exposure during F0 pregnancy, the
relationship among F0, F1, and F2 would be multigenerational, as the effects of direct
exposure to the drug span more than two generations. The paired relationships between
F0-F1 and F1-F2, however, would be intergenerational, as these pairs span only two
generations post-direct drug exposure. A depiction of multi-, inter-, and trans-generational
types of inheritance is shown in Figure 2.
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Figure 2. Illustration of multi-, inter-, and trans-generational relationships resulting from
parental drug exposure. When F0 males or females are exposed to drugs of abuse in
adolescence or adulthood, the germ cells that give rise to the F1 generation are directly
exposed, resulting in intergenerational transmission. Because the germ cells of the F1
generation were not directly exposed, the F2 generation represents transgenerational
transmission. When F0 pregnant or postpartum breastfeeding females are exposed, the
F1 generation and their germ cells that will give rise to the F2 generation are also directly
exposed, resulting in intergenerational transmission. For both of these scenarios, the F3
generation is the first without direct drug exposure and therefore represents
transgenerational transmission. As F0-F2 generations have direct drug exposure in the
case of pregnant or postpartum females, the relationship among the three generations
represents multigenerational transmission. Red stars represent direct exposure to that
particular generation while yellow stars represent direct exposure to the germ cells. Figure
reproduced from Odegaard, Pendyala, and Yelamanchili, 2021.91
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Opioid Use
Opiate analgesics have a long history of clinical use in the treatment of chronic
pain. First derived from opium in 1803, morphine became widely used with the
technological innovation of the perfected hypodermic syringe in 1853, which allowed for
faster delivery of morphine into the blood or tissue. The American Civil War (1861-1865),
the Prussian-Austrian War (1866), and the Franco-Prussian War (1870) also rapidly
increased the use of morphine for the reduction of pain and relief from dysentery, often
leading to a dependence later deemed “soldier’s disease” or the “army disease.” 1 In
England, morphine was first recommended for treatment of cancer pain in the 1950s. 95
Taken orally or by injection, morphine is still widely used today for acute and chronic pain
management. Unfortunately, the pain-relieving nature of opioids contribute to their illicit
and excessive use, affecting the behavior of the user.96 Recently, the increased abuse of
prescription and non-prescription opioids has resulted in a severe public health crisis
throughout large swaths of America.97-99 In 2017, over two-thirds of drug-overdose deaths
resulted from opioid abuse,100 and opioid overdose-attributed deaths have tripled since
the turn of the new millennium.101 Of the opioids used today, perhaps the most notorious
are morphine, heroin, and oxycodone. Chemical structures for morphine (CID 5288826),
heroin (CID 5462328), and oxycodone (CID 5284603) as published on PubChem102-104 are
shown in Figure 3.
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Figure 3. Chemical structures of morphine, heroin, and oxycodone, as published by
PubChem.
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Routes of Administration
The route of administration of opioids has important implications on an individual’s
health, including risk of dependence, susceptibility to infection, and experience of any
route-specific health complications.105 The most common routes of administration for
opioids are oral, intravenous, intramuscular, and subcutaneous.106 Varying routes of
administration are chosen based on the ease and tolerability of administration as well as
the ability to target specific sites of opioid receptors for localized or generalized effects.107
Although it is the simplest and well-tolerated route, oral administration of opioids may not
always be an option, particularly when oral access is limited. Oral administration and the
subsequent first pass metabolism may also affect the function of the drug. For example,
oral administration of fentanyl results in extensive hepatic metabolism, affecting the utility
of the drug.107 To remedy this, opioids have been prepared in immediate- or slow-release
forms. Immediate-release preparations have an onset of action of 20-30 minutes, with
analgesia obtained in 45-60 minutes and a duration of action of 3-4 hours. Slow-release
preparations allow for a higher initial dose to be administered and a sustained plasma
level with a duration of action of 12-24 hours. The onset of action, however, takes 3-4
hours to peak, which is much slower than that of the immediate-release option.107
Intravenous administration allows for a faster onset of pain relief that is effective and suited
to perioperative use. Disadvantages of this route include the need for cannula insertion
and its maintenance. Intramuscular and subcutaneous administrations allow an injected
opioid to be absorbed into the systemic circulation of the body. Opioid absorption of
intramuscular injections may vary, however, depending on tissue perfusion; low perfusion
rates may result in poor uptake into the systemic circulation and lead to inadequate
analgesia. Subcutaneous injections are preferable to intramuscular injections as they can
be administered via an indwelling cannula and do not risk nerve injury that may
accompany intramuscular injection.107 Pharmacological advancements continue to
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address the safety and efficacy of opioids to allow for alternative routes of administration
that are best suited to individual patients and their conditions.
Mechanism of Action
Whether used licitly or illicitly, opioids activate three types of receptors (mu, MOR;
delta, DOR; kappa, KOR). These receptors are dispersed throughout the CNS and
peripheral tissues. MOR are generally found in the brainstem and medial thalamus. They
are required for supraspinal analgesia, respiratory depression, euphoria, sedation, and
physical dependence. DOR are located in the brain and may be responsible for
psychomimetic and dysphoric effects. KOR are located in the limbic and diencephalic
areas, the brain stem, and the spinal cord, and they are responsible for spinal analgesia,
sedation, dependence, and dysphoria.108
As G-protein coupled receptors (GPCRs), opioid receptors are activated when
opioid agonists bind to the receptor and activate the G-protein (Figure 4). The activated
G-protein then moves to its target, like an enzyme or an ion channel, where these targets
can alter phosphorylation via the inhibition of cyclic AMP (cAMP). cAMP, as a second
messenger, contributes to the activation of protein kinases that can impact gene
transcription proteins as well as gene transcription.108 Opioid receptors on the presynaptic
terminals of nociceptive fibers can indirectly inhibit voltage-dependent calcium channels,
decreasing cAMP levels and blocking the release of pain neurotransmitters, which results
in analgesia. Opioids can antagonize NMDA receptors and activate descending serotonin
and norepinephrine pain pathways in the brainstem. The stimulation of the NMDA
receptors may also result in neuropathic pain and the development of tolerance.108 Opioids
can also activate the receptors on GABA neurons, thereby inhibiting the release of GABA
in the VTA and allowing dopaminergic neurons to increase firing, resulting in extra
dopamine in the NAc and creating a pleasurable sensation.108 The NAc is largely affected
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by the binding of opioids to their receptors in the dopaminergic reward system and
undergoes changes in density of the dendritic spines,96 effectively altering the plasticity of
the dendritic spines during nervous system development. This neural plasticity is critical
in the development of SUDs and other ingrained behaviors.
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Figure 4. Simplified mechanism of action of opioids using morphine as an example of an
opioid receptor agonist. Created using Biorender.com.
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Morphine
Morphine (C17H19NO3) is a potent analgesic primarily used in hospitals to combat
severe pain. Structurally, morphine is a benzylisoquinoline alkaloid with two ring closures
that is considered part of the phenanthrene group of opioids.108 Approximately 40-50% of
an orally administered dose reaches the CNS; this occurs within 30 minutes for an
immediate release form of morphine and within 90 minutes for any extended release
form.108 The half-life of morphine is approximately 2-3 hours.109 While the initial stage of
morphine metabolism is carried out by CYP450, morphine is predominantly metabolized
by glucuronidation by UGT2B7 to produce morphine-6-glucuronide and morphine-3glucuronide in a ratio of 6:1.110 Glucuronidation occurs almost immediately after morphine
enters the serum in both hepatic and extra hepatic sites.111 Morphine-3-glucuronide in high
enough concentrations is believed to potentially lead to hyperalgesia, 112 and morphine-6glucuronide is believed to be responsible for the majority of morphine’s analgesic
effects.113

Demethylation

of

morphine

via

CYP3A4

and

CYP2C8

produces

normorphine.114
While morphine may be effective for pain relief, there are potential adverse side
effects such as tolerance and addiction as well as molecular alterations.115 Morphine’s
powerful analgesic effects stem from its role as an opioid receptor agonist. By binding to
MOR and KOR, morphine blocks the transmission of nociceptive signals, signals painmodulating neurons in the spinal cord, and inhibits primary afferent nociceptors to the
dorsal horn sensory projection cells.116 Morphine also activates the reward pathway by
binding to receptors in the VTA and NAc, leading to an influx of dopamine in the
synapse.117
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Heroin
The result of a chemical modification to morphine, heroin (C21H23NO5) is about
three times as potent as its parent drug.1 Unlike morphine, which can be prescribed, heroin
is an illicit substance. Like other opioids, heroin acts agonistically to the three opioid
receptors.118 Heroin activation of MOR contributes to analgesic effects, respiratory
depression, and euphoria;119 KOR activation contributes to a degree of analgesia as
well,119 and DOR activation is more involved in spinal analgesia. When injected, heroin is
metabolized by sequential deacetylation of two separate ester bonds to form 6monoacetylmorphine, a more potent MOR agonist than morphine,119 which can further be
metabolized to morphine and morphine metabolites.118 When taken orally, heroin
undergoes first-pass metabolism to morphine via deacetylation. Therefore, unlike
intravenous administration, oral ingestion does not cause a rapid onset of effects
conferred by 6-monoacetylmorphine.120 The preferred method of injecting heroin, coupled
with impaired judgment can lead to needle sharing, which can increase the risk of
contracting infectious diseases such as HIV and hepatitis.121
Oxycodone
Structurally similar to morphine, oxycodone (oxy; C18H21NO4) has been established
as a potent and widely abused prescription opioid. Designed for pain management, oxy
operates primarily as a full agonist to MOR.122 The binding of oxy to MOR subsequently
inhibits neurotransmitter release by decreasing cAMP production.122 Importantly, oral
doses of extended release oxy are thought to be twice as potent as a similar dose of
morphine,123 contributing to its popularity and abuse. The bioavailability of oxy is high in
oral dosage, with a half-life of 2.5-3 hours. Like morphine, oxy is metabolized by
glucuronidation by CYP3A4 and CYP3A5 to noroxycodone, and by CYP2D6 to
oxymorphone.124 Both oxymorphone and noroxycodone can be further metabolized to
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noroxymorphone by CYP3A4 and CYP2D6. While oxy itself contributes the majority of the
analgesic effect, its metabolites also act as opioid agonists. Oxy and its metabolites can
diffuse across the blood brain barrier or may be actively transported by an unknown
mechanism.125 With oxy’s utility as a treatment for moderate to severe pain in pregnant
women, it is important to note than oxy and its metabolites can also pass through the
breastmilk as well as through the placenta to be distributed to the offspring.126

Generational Inheritance and Opioid Abuse
The ongoing opioid epidemic in the United States and worldwide is characterized
by an increase in use of licit and illicit opioid substances, such as prescription opioids, illicit
heroin, and illicitly-produced fentanyl. While steps have been taken by the FDA to limit
opioid abuse and misuse, the potential for addiction remains an issue, especially when
individuals turn to cheaper, illicit opiates as an alternative to prescription opioids. 127
Further,

opioids

are

commonly

prescribed

to

postpartum

women,

often

in

abundance,128,129 making pregnant women a particularly vulnerable group in the opioid
epidemic. With regard to generational studies and opioid exposure, studies involving in
utero exposure to opioids are particularly critical, as these may result in neonatal opioid
withdrawal syndrome (NOWS) or neonatal abstinence syndrome (NAS). Neonates with
NOWS/NAS exhibit high-pitched cries, tremors, difficulty feeding, hypertonia, and
breathing issues.130 In the context of in utero opioid exposure and NOWS/NAS, the fetal
origins of adult disease hypothesis, first posited by Dr. David Barker in 1995,131 is
particularly interesting. This hypothesis states that risk factors from intrauterine
environmental exposures affect fetal development during sensitive periods, and increase
the risk of specific diseases in adult life.132 Indeed, prenatal exposure to opioids has been
associated with smaller head size, lighter birthweights, and shorter body lengths in
neonates.133-138 Moreover, not only do young adults exposed to heroin prenatally exhibit
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cognitive and motor function deficits,139,140 but they may also have an 8-fold increased risk
of depression, a 3-fold increased risk of attention disorders, and a 16-fold increased risk
of substance use disorders.141 As substance use disorder is considered a disease, it is
critical to understand how the generational effects of opioid exposure manifest in not only
newborns, but adults as well.

Animal Studies
Several animal studies using rats and mice have been conducted to determine
multi-, inter-, and transgenerational effects of opioid exposure, with most studies being
conducted using morphine, heroin, and oxycodone. The studies discussed in this section
involve maternal, paternal, parental, and perinatal exposure paradigms. Maternal and
paternal studies were conducted in adolescent and adult models. Maternal models are
also part of the perinatal paradigms as the opioids were administered to the mother and
passed to the offspring through the placenta (in utero exposure) or via the breastmilk
(postnatal exposure). In parental paradigms, both parents were exposed to opioids.
Morphine
A number of studies using rats have been conducted to determine the generational
effects of parental morphine use on offspring. Chronic morphine exposure during
adolescence has been shown to significantly impact male reproductive parameters, as
evidenced by reduced seminal vesicle and testes weights,142 and delay sexual
maturation.143 Additionally, offspring born to males with adolescent morphine exposure
had several endocrine deficits in adulthood. Specifically, adult male offspring born to
morphine-treated males had lower serum testosterone and luteinizing hormone levels and
higher adrenal weights.142 In female offspring, serum corticosterone and β-endorphin
levels were significantly higher, but no differences in reproductive endocrine status were
observed. Interestingly, F1 and F2 males descended from adolescent morphine-exposed
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dams had blunted corticosterone secretion, an effect that was specific to offspring from
females exposed to morphine during adolescence as opposed to those exposed during
adulthood.144 These males also had significantly lower levels of paraventricular nucleus
(PVN) corticotropin releasing hormone (CRH). F2 males also exhibited dysregulated MOR
expression in the PVN.144 Interestingly, on a fat-sugar diet (FSD), F1 males born to
adolescent morphine-exposed females had increased weight gain, fasting glucose,
insulin, and corticosterone levels, as well as increased neuropeptide Y (NPY), a potent
orexigen.143 Maternal opioid exposure in adolescence appears to interact with F1 offspring
diet to further disrupt hypothalamic and neuroendocrine systems that influence sexual
maturation, energy metabolism, synaptic plasticity, and possibly immune function.143
Interestingly, dams with adolescent morphine exposure were shown to have
reduced levels of prolactin secretion postpartum, suggesting that morphine use during the
pubertal period may affect prolactin secretion into adulthood, potentially affecting the
maternal behavior and subsequent behaviors of the offspring.145 Indeed, Johnson et al.
found that adolescent exposure to morphine did affect maternal behavior, with exposed
mothers spending less time nursing and grooming pups and more time away from the nest
and engaging in self-directed behavior.146 Perhaps as a result of maternal effects, female
offspring of exposed dams exhibited increased anxiety-like behavior.147,148 Further, male
and female offspring appeared to develop a tolerance for the sedative effects of morphine
more quickly than offspring born to untreated dams.147,148 Male offspring also
demonstrated decreased rough and tumble play behaviors, while females exhibited a
tendency toward increased rough and tumble play, demonstrating sex-specific effects of
maternal adolescent morphine exposure on the F1 generation.146 To determine changes
in the reward system, Vassoler et al. used conditioned place preference (CPP) and
locomotor sensitization. F1 animals showed increased sensitivity to morphine, and
females showed increased locomotor activity when compared to males.149 Additionally, all
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F1 animals born to morphine-exposed dams had decreased MOR protein expression in
the VTA, while only females had an increased expression of MOR in the NAc. This
differential expression of MOR in the NAc and VTA may contribute to the increased
sensitivity to morphine seen in these offspring born to morphine-exposed mothers.149
Transgenerational effects of maternal adolescent morphine exposure have also
been reported. Male offspring of morphine-exposed dams had previously shown
enhanced locomotor sensitization in response to repeated morphine exposure.147 As
dopamine agonists have been shown to affect locomotor sensitization, Byrnes et al.
sought to investigate the effect of quinpirole, a dopamine D2/D3 receptor agonist, on
locomotor sensitization in F1 and F2 male progeny of morphine-exposed F0 dams.150
Quinpirole treatment resulted in an increased locomotor response and also increased
plasma corticosterone levels in both generations. Repeated administration of quinpirole
resulted in increased expression of KOR and dopamine D2 receptor in the NAc of the
males in both generations. Together, these data may suggest the presence of functional
and transgenerational neuroadaptations within the NAc that are transmitted across two
generations following maternal adolescent exposure to opiates.150
The effects of adolescent morphine exposure are not limited to females, however.
Paternal, maternal, and parental adolescent morphine exposure have been shown to
increase anxiety-like behavior in male offspring, depressive-like behavior in female
offspring, and enhanced morphine consumption in both sexes during adolescence. 151
Interestingly, parental exposure to an enriched environment reduced anxiety- and
depressive-like behaviors and voluntary morphine consumption in the offspring, offering a
potential preventative measure in the development of these traits in future offspring. 151
Further, paternal adolescent morphine exposure also altered pain perception152 and
several electrophysiological properties in the locus coeruleus of male progeny.153
Additionally, F0 male and female parents chronically exposed to morphine in adolescence
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had increased levels of hippocampal TNF-α, an inflammatory cytokine; F1 male and
female offspring of these parents showed the same increase in hippocampal TNF-α.154
Fathers, but not mothers, also had lower levels of S100B, another key protein in
neuroinflammation. This decrease in S100B was also reported in the male and female
offspring, suggesting that adult exposure to morphine can induce hippocampal
modifications intergenerationally.154 Additionally, males born to morphine-exposed fathers
exhibited morphine tolerance and decreased firing of VTA dopamine neurons.155
Adolescent morphine exposure in males may also impact future substance abuse
of the F1 generation. Male and female F1 progeny have delayed acquisition and
decreased intake of cocaine. In addition, they have blunted self-administration levels
compared to control rats. Female offspring also had increased levels of morphine intake
during acquisition and increased self-administration for oxycodone.156 Surprisingly, even
following

acquisition of

morphine self-administration, males and females still

demonstrated a blunted effort for cocaine. Brain-derived neurotrophic factor (BDNF), an
important factor in hippocampal synaptic plasticity, neurogenesis, and modulation of
learning and memory, was increased in the prefrontal cortex (PFC) in F1 male and female
offspring. Together, these data identify systems that are vulnerable to the adolescent
parental exposure and how they may impact drug use of future generations.
Prenatal morphine exposure studies in animals have offered insight into the
developmental effects on learning and memory. Prenatal morphine exposure has been
shown to affect hippocampal neuron viability and expression of proteins crucial for
synaptic plasticity. Increased hippocampal neuron apoptosis, decreased CaMKII
(Ca2+/calmodulin-dependent kinase II; essential for the induction of synaptic potentiation
and memory formation) activity, and decreased BDNF expression have been reported in
offspring that were prenatally exposed to morphine.61,157 Prenatal morphine exposure has
also been shown to decrease post-synaptic density protein 95 (PSD-95; implicated in the
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regulation of synaptogenesis, synaptic plasticity, learning and memory) expression in the
hippocampus.158,159 Prenatal exposure also reduced the magnitude of the expression of
nitric oxide synthase (nNOS), LTD (a mechanism of learning and memory), and
phosphorylated CREBSerine-133 (an important transcription factor for mammalian learning
and memory) in the hippocampal CA1 region of post-natal day 14 (P14) pups.
Interestingly, prenatal coadministration of dextromethorphan, an antitussive drug that has
been shown to mitigate morphine tolerance and withdrawal,160,161 during pregnancy and
throughout lactation significantly attenuated these changes in the hippocampus,
presenting a potential therapeutic strategy for combatting these effects of prenatal
morphine exposure.158
Intriguingly, as another cellular process underlying learning and memory, LTP has
also been reported to be reduced in offspring prenatally exposed to morphine.58-61 Niu et
al. suggested that depressed LTP in the morphine group may denote a change in
GABAergic inhibition; indeed, a loss of GABA-containing neurons in the dentate gyrus
(DG) area of the morphine group was observed.59 Subsequent behavioral tests to
elucidate the impact of these molecular changes have shown altered long- and short-term
learning and memory tasks,157,158 impaired working and cued reference memory,159
impaired spatial learning and memory,59,61,162 and enhanced maintenance but impaired
acquisition of contextual fear memory60 in rats prenatally exposed to morphine. Further,
prenatally exposed offspring exhibited reduced anxiety-like behavior and no differences in
locomotor activity,60 contrary to what was reported in the adolescent morphine studies
mentioned previously. Intriguingly, postnatal exercise and enriched environment was
shown to improve deficits in spatial learning, hippocampal LTP, and BDNF levels caused
by prenatal morphine exposure.61
Adult parental exposure prior to pregnancy and gestation has also been shown to
affect behavior and hippocampal signaling. F0 males and females exposed to morphine
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as adults yielded F1 offspring that exhibited anxiety-like behavior163,164 and dendritic
retraction in the DG of the hippocampus in adulthood.164 Further, CRH levels in the plasma
and CSF (cerebrospinal fluid), along with CRH receptor 1 mRNA levels, were also
increased in F1 progeny while protein kinase C (PKC) levels were decreased. 163
Additionally, insulin-like growth factor (IGF)-2 signaling in the granular zone of the DG was
downregulated in these F1 animals. Interestingly, overexpression of IGF-2 prevented
anxiety-like behaviors in these offspring. Further, exposure to an enriched environment
during adolescence corrected the reduction of hippocampal IGF-2 expression, normalized
anxiety-like behavior, and reversed dendritic retraction in the adult offspring.164 This study
suggests that IGF-2 and an enriched environment may be potential forms of intervention
to prevent anxiety and brain atrophy in the offspring of parental opioid exposure.
Further, males born to parents with adult morphine exposure exhibited significant
memory impairments and tolerance to morphine that were more prominent with maternal
morphine exposure than either paternal or parental exposure.165 Additionally, maternal
adult morphine exposure resulted in diminished spatial memory in males in the F1 and F2
generations.166 Hippocampal Mecp2, a transcriptional repressor, and Hdac2, a histone
deacetylase important in cognitive function, were also significantly upregulated in the
males of both generations.166 These changes were not seen in the female F1 and F2
progeny, suggesting sex-specific alterations resulting from maternal adult morphine
exposure. Ellis et al. have also shown that paternal morphine exposure produces sexspecific impairments in object recognition memory in female offspring. 167 Additionally,
offspring born to parents with adult morphine exposure had decreased object recognition,
possibly due to decreased histone H3 acetylation and ΔFosB levels in the PFC and
hippocampus.168 Interestingly, nociception was reduced in offspring born to adult
morphine-exposed parents, and these offspring also had a low neuronal firing rate and
enhanced opioid receptor expression in the NAc.169
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Furthermore, F1 male progeny of morphine-exposed parents had a greater
preference for morphine and more anxiety-like behavior; these effects were not seen in
the F2 generation.170 F1 male progeny also exhibited increased expression of D1 and D5
dopamine receptors in the PFC and NAc; D5 and D2 receptors were decreased in the
hippocampus. The D4 dopamine receptor was augmented in striatum and hippocampus
and decreased in the PFC.170 Alterations in dopamine receptor expression within the
reward system may be one mechanism responsible for these behavioral changes in F1
offspring. Interestingly, injection of SCH23390, a dopamine D1 receptor antagonist, into
the PFC and the hippocampus improved spatial memory that was previously reported to
be impaired in males born to parents with adult morphine exposure.171
Heroin
Rat models of parental heroin exposure have provided insight into how heroin
exposure in the F0 generation can affect subsequent generations. In one
transgenerational study of adolescent paternal exposure, F0 male exposure resulted in
smaller F1 litter sizes as well as heightened anxiety and increased aggression in both F1
and F2 offspring; these effects appeared to subside in the F3 generation.172 While paternal
heroin exposure has only recently been explored, several studies of prenatal heroin
exposure have been done in mice models. For example, Zhu et al. found that heroinexposed pups had a marked reduction in birth weight, and the postnatal weight gain in
these pups was significantly lower than that of controls, particularly in female pups. 173
These female pups also showed a significant increase in ambulation and rearing,
suggesting that prenatal heroin exposure could result in a sex-specific delay of postnatal
development and learning.173
With regard to learning, prenatal heroin exposure has been shown to affect the
hippocampus and memory-associated behaviors. Prenatal exposure to heroin in mice
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resulted in increased expression of hippocampal caspase-3 and Bax and decreased
expression of Bcl-2, which together may enhance neuronal apoptosis and impair
hippocampus-dependent learning and memory.174 Interestingly, prenatal heroin exposure
was also shown to decrease dendrite length and branch number in the somatosensory
cortex.175 Further, mice prenatally exposed to heroin displayed behavioral deficits in eightarm and Morris mazes174,176 and exhibited impaired short-term spatial memory as
adults.175 These mice also had increased synaptic activity in cholinergic hippocampal
cells.176 Additional research found that these hippocampus-related behavioral deficits may
be linked to the cholinergic receptor-mediated translocation of PKC isozyme PKCγ, which
has a role in learning and memory.177-179 Interestingly, the alterations in cell signaling and
subsequent behavior deficits found in prenatal mice models were also reported with prehatch heroin exposure in chickens, where heroin exposure affected imprinting behavior
and PKCγ.176
Oxycodone
Several studies of perinatal oxycodone have been conducted in rats to deduce the
negative effects of oxycodone exposure in utero or postnatally. One study of prenatal
oxycodone exposure found that rat pups exposed in utero had congenital malformations
of the face, mouth and vertebrae as well as intrauterine growth retardation. 180 In
adolescence, these animals had lower body and kidney weights. Additionally, endothelin
receptor A expression was higher at P1 but appeared to return to baseline by P7, P14,
and P28. Conversely, endothelin receptor B expression was lower in the exposed offspring
at P1 and P7, returned to baseline at P14, and was increased by P28. As the endothelin
receptors are important in normal development of the CNS, the alterations in their
expression levels in these offspring may suggest a delay in CNS development.180
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Additionally, prenatal oxycodone exposure rat models have shown alterations in
cardiovascular responses as well as behavior. Rats exposed to oxycodone in utero
showed subtle alterations in stress cardiovascular response that subsided with age. In
adulthood, these rats exhibited impaired memory of stress conditioning learned with
adolescent tail shock testing, suggesting the presence of a memory deficit associated with
prenatal oxycodone exposure.181 Indeed, prenatal oxycodone exposure has been shown
to impair spatial learning and memory.182 Prenatal oxycodone exposure rats made a
greater number of reference memory errors in the beginning of radial arm maze testing.
They also had a deficit in memory retention when assessed by T-maze five days postacquisition training. In Morris water maze, prenatally exposed rats exhibited poor
acquisition during long inter-trial intervals only, with no deficit reported during short intertrial intervals. Exposed rats also had an increased latency to find and greater distance
traveled to the platform in the Morris water maze.182 Using several spatial memory tasks,
this study by Davis et al. indicated that prenatal oxycodone exposure consistently impairs
learning and memory.182 Interestingly, other behavioral paradigms have linked prenatal
oxycodone exposure and hyperactivity in adult rats, which is consistent with hyperactivity
problems identified in children exposed to opiates in utero.183
In an oxycodone self-administration study, offspring exposed in utero
demonstrated region-specific effects of oxycodone exposure on MOR-1 at P1; specifically,
MOR-1 expression was significantly decreased in the midbrain and forebrain of exposed
females.184 Further, the number of ultrasonic vocalizations by pups exposed to oxycodone
in utero varied over time depending on oxycodone intake and pup development. For
example, on P3, higher oxycodone intake was associated with fewer vocalizations, while
by P9 higher oxycodone intake was associated with a greater number of vocalizations.
Maternal oxycodone self-administration and dose-dependent alteration of the maternal-
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offspring dyad may have resulted in sex- and region-specific effects on early measures of
neurodevelopment.184
Our own laboratory studies have shown that prenatal oxycodone exposure has
recently been shown to alter the cargoes of extracellular vesicles (EVs), key players in
cell-cell communication.185 Through RNA-sequencing, distinct miRNA signatures were
identified in EVs isolated from P14 rat brains. The gene targets of the dysregulated
miRNAs identified in offspring exposed to oxycodone in utero (IUO) or postnatally (PNO)
were largely related to the regulation of key functional pathways associated with brain
development, with the more impacted group being the IUO. Additionally, treatment of
primary neurons with these EVs isolated from IUO brains caused significant reductions in
dendritic spine density compared with treatment of PNO or control brain-derived EVs.
Dopamine D1 expression was also increased in synaptosomes isolated from P14 IUO
brains, potentially a result of the upregulated miR-504 cargo of IUO EVs, which may also
play a role in the loss of dendritic spines.185

Human Studies
Most human studies regarding generational effects of opioid exposure combine
data from different opioid exposure cases together and consider them as one opioidexposure group. Additionally, most of these studies discuss prenatal opioid exposure and
its consequences on the children as they age. Such prenatal exposure studies focus on
the immediate outcomes in the F1 children, making a majority of these studies
intergenerational. Indeed, short-term consequences of opioid exposure are wellcharacterized,186 but the long-term, intergenerational consequences require further study.
This section will discuss combined opioid exposure studies, where different exposures to
morphine, heroin, oxycodone, etc. have been grouped into one opioid exposure group, as
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well as opioid-specific studies, which consist mainly of heroin with or without
polysubstance abuse.
Recently, in utero opioid exposure has been significantly associated with higher
risks of fetal growth restriction, preterm birth, lack of normal development, childhood
conduct disorder or emotional disturbance in preschool children, and attentiondeficit/hyperactivity disorder (ADHD) in older children.187 A longitudinal study of 8,509
mother-child pairs included 454 mother-child pairs exposed to opioids and 8,055 control
mother-child pairs not exposed to opioids. As most of the sample included urban, lowincome, and minority ethnic groups, the higher incidence rates of NAS serve to highlight
the plight of prenatal opioid exposure in urban, low-income populations in the inner cities
of the United States.187 Infants born to these mothers had lower gestational age, lower
birthweight, and smaller size for gestational age. Within the first six years of age, exposed
children had a higher risk of diagnosis with conduct disorders, emotional disturbance, and
deficits in physiological development; after six years of age, the likelihood of being
diagnosed with ADHD increased in these children. This study adeptly describes the opioid
epidemic as an intergenerational problem.187
A recent meta-analysis of publications spanning from 1993 to 2018 showed the
extent of neurodevelopmental outcomes reported in children born to opioid-dependent
mothers.188 Exposed children had lower infant cognitive and psychomotor scores, lower
general cognition/IQ and language scores, and higher parent-rated internalizing,
externalizing, and attention problems. Overall, this analysis showed that prenatal opioid
exposure increases the risk of adverse neurodevelopment in children at least through
middle childhood. Important to note, however, is that this meta-analysis only covered three
school-aged reported outcomes, limiting the ability to assess longer-term impacts of
prenatal opioid exposure.188 More importantly, this limitation highlights an overall limitation
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in the field; more longitudinal human studies of prenatal opioid abuse are critical in
understanding long-term intergenerational effects of opioid exposure.
In an fMRI study of prenatal drug exposure, which included prenatal exposure to
heroin, Geng et al. found that prenatal drug exposure was related to decreased memory
performance and altered brain activation during memory encoding.189 Interestingly, the
deficits in memory in adolescents with prenatal drug exposure may stem from variations
in encoding rather than in retrieval processes, meaning that potential interventions should
focus on encoding rather than retrieval to improve memory performance in these children.
This study conducted in 5- to 14-year-old children showed that prenatal exposure to drugs,
heroin among them, has long-term effects on memory.189 Interestingly, a 2010
neuroimaging study found that prenatally-exposed children had smaller intracranial and
brain volumes as well as thinner cortex of the right anterior cingulate and lateral
orbitofrontal cortex. The volumes of the anterior cingulate, orbitofrontal cortex, and
accumbens area were associated with cognitive ability and behavior problems.190
Providing a paternal/maternal consideration of intergenerational effects beyond
prenatal exposure, a recent study by Griesler et al. investigated the intergenerational
patterns of nonmedical prescription opioid (NMPO) use in adolescents (12- to 17-yearolds) and their parents, providing a paternal/maternal consideration of intergenerational
effects beyond prenatal exposure. Maternal use of NMPO had a stronger association with
adolescent use than paternal use.191 Use of other drugs also affected both parental and
offspring NMPO use. In addition to parental drug use, the quality of the parent-child
relationship, adolescent drug use of non-NMPO substances, risk of drug use, drug use by
peers, depression, and delinquency were each associated with adolescent NMPO use.
These authors therefore suggested that parent-based interventions targeted at NMPO use
among youth should not only address parental NMPO use but should also promote
positive parenting practices, such as monitoring and reduced conflict.191 In a similar study
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considering prescription opioids, Kerr et al. found that paternal opioid misuse and maternal
opioid use were associated with the child’s substance use; further, parental prescription
opioid misuse or use also predicted child use of alcohol, marijuana, or tobacco by
adolescence.192
In an older study that assessed attentional performance and cardiac reactivity to
attentional demand, boys (aged 7 to 12) who were exposed to opioids in utero were
compared to boys whose mothers began using illicit substances after the child's birth
(environmental controls), and boys whose mothers were non-drug users.193 Vagal tone, a
measure of heart-rate variability, was measured during an attention task. When distractors
were added to the task, opioid-exposed boys failed to suppress vagal tone. Interestingly,
both groups with parental opioid exposure made fewer correct responses on this task,
indicating that environmental influences, in addition to prenatal opioid exposure, impact
attentional performance. The authors concluded that normal physiological responses to
increased attentional demand may be impaired in opioid-exposed male children.193
Of the opioids discussed in this review, heroin appears to be the most studied in
human subjects. Illicit heroin use during pregnancy has been associated with several
adverse effects in mothers and infants.188 Prenatal exposure to heroin resulted in reduced
head circumference, birth length, and birth weight,194 but it has not been associated with
congenital malformations.195 Additionally, one small retrospective study showed that
93.9% of heroin-exposed infants developed drug withdrawal symptoms within 24 h of
birth.196 This withdrawal, or NAS, may impact language and cognition development.197
In another interesting study, children (5-6 years of age) born to heroin-dependent
mothers were compared to those born to heroin-dependent fathers and three control
groups. Out of 83 children born to heroin-dependent mothers, five had significant
neurological damage. Of the 76 children born to heroin-dependent fathers, six had
significant neurological damage.198 Further, the children with maternal heroin exposure
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had lower birthweight and lower head circumference than controls. Parental heroin
dependence also resulted in higher hyperactivity, inattention, and behavioral problems in
the children. Interestingly, children of heroin-dependent mothers that had been adopted
at an earlier age functioned similarly to controls while those raised by their birth mothers
functioned significantly lower. This study implicates the role of home environment in the
developmental outcomes of children born to heroin-dependent parents.198
Indeed, prenatal drug abuse, unstable parental care, and low birthweight may
contribute to the vulnerability of exposed offspring.140 A study of 17- to 21-year-old
individuals prenatally exposed to heroin and poly-substance abuse revealed lower
cognitive functions that appeared to be partially mediated by lower birthweights.140 Further,
the individuals exposed to the least amount of drugs and who had more stable parental
care had the best cognitive scores compared to those with unstable homes or mothers
who used more drugs during pregnancy.140 Interestingly, parental factors have previously
been shown to play a role in the increased risk of substance use disorders reported in
children of heroin-dependent parents.141 Nygaard et al. continued their investigation of
prenatal heroin and polysubstance abuse by studying the mental health of these
individuals.199 Similar to the findings by Vidal et al.,141 a higher proportion of these
individuals reported lifetime experiences with major depressive disorder, alcohol abuse,
and ADHD.199 These individuals also scored higher on the aggressive behavior scale and
had more sexual partners and were younger at their sexual debut.199

Summary and Conclusions
Overall, SUD resulting from biochemical alterations that occur within the reward
circuitry of the brain is often characterized by maladaptive and compulsive behaviors of
the user. In recent years, opioid use disorder (OUD), specifically, has been deemed an
epidemic in the United States. As pregnant women continue to be a vulnerable population
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within this epidemic, potentially impacting future generations, understanding multi-, inter-,
and trans-generational inheritance is critical. As current human studies of prenatal opioid
exposure have yet to extend to long-term inter- or trans-generational studies, preclinical
animal models are working to fill in the knowledge gaps. While most animal studies have
considered the generational impacts of morphine exposure, the need to investigate other
opioid exposures is paramount. As an opioid commonly prescribed to women for
pregnancy pain, oxycodone is an important opioid to investigate in the context of
generational effects. The present work, presented as three chapters, investigates and
characterizes the effects of pre- and post-natal oxycodone exposure on the F1 and F2
generations to fill the knowledge gaps surrounding this important opioid and its
generational impact. Chapter One describes the effects of oxy exposure on the F1
generation, specifically with regard to biochemical, electrophysiological, and behavioral
changes; this chapter includes data first published in Translational Psychiatry.138 Chapter
Two further explores the impact of oxy exposure on the F1 generation through the
characterization of synaptic vesicle proteomes. Lastly, Chapter Three characterizes the
intergenerational effects of oxy exposure in both F1 and F2 generations with regard to
physical development, gene expression, and behavior; this chapter contains data first
published in Frontiers in Cell and Developmental Biology.200 These chapters are followed
by an overall discussion to encompass all findings and future avenues of this research.

38

Materials
Antibodies
Primary Antibodies
Name

Company

GAPDH
Monoclonal, mouse, 1:2000

Invitrogen (Carlsbad, CA, USA)

LAMTOR4
Monoclonal, rabbit, 1:750

Cell Signaling (Danvers, MA, USA)

MEGF8
Polyclonal, rabbit, 1:1000

Bioworld Technology (St. Louis Park, MN,
USA)

PSD95
Monoclonal, mouse, 1:2000

Invitrogen (Carlsbad, CA, USA)

PSMC6
Monoclonal, mouse, 1:1000

Abcam (Cambridge, UK)

SNAP25
Polyclonal, rabbit, 1:2000

Sigma Aldrich (St. Louis, MO, USA)

SYP
Polyclonal, rabbit, 1:5000

Invitrogen (Carlsbad, CA, USA)

Secondary Antibodies
Name

Company

anti-mouse IgG

Thermo Fisher Scientific (Waltham, MA,
USA)

peroxidase-labelled, 1:5000
anti-rabbit IgG
peroxidase-labelled, 1:2000; 1:10000

Thermo Fisher Scientific (Waltham, MA,
USA)
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Chemicals and Reagents
Name
Acetonitrile
ATP-Mg
Bovine Serum Albumin
CaCl2
Cs-methanesolfonate
EGTA
Formic Acid
Glucose
GTP-Na2
HEPES
KCl
L-ascorbic acid
Mass Spectrometry-grade Trypsin
MgSO4
NaCl
NaH2PO4
NaHCO3
NA-pyruvate
NMDG
Nonfat Milk
Oxycodone hydrochloride
Phosphocreatine
Picrotoxin
Protease Inhibitor

Company
Thermo Fisher Scientific (Waltham,
MA, USA)
Thermo Fisher Scientific (Waltham,
MA, USA)
Thermo Fisher Scientific (Waltham,
MA, USA)
Thermo Fisher Scientific (Waltham,
MA, USA)
Thermo Fisher Scientific (Waltham,
MA, USA)
Thermo Fisher Scientific (Waltham,
MA, USA)
Thermo Fisher Scientific (Waltham,
MA, USA)
Thermo Fisher Scientific (Waltham,
MA, USA)
Thermo Fisher Scientific (Waltham,
MA, USA)
Thermo Fisher Scientific (Waltham,
MA, USA)
Thermo Fisher Scientific (Waltham,
MA, USA)
Thermo Fisher Scientific (Waltham,
MA, USA)
Thermo Fisher Scientific (Waltham,
MA, USA)
Thermo Fisher Scientific (Waltham,
MA, USA)
Thermo Fisher Scientific (Waltham,
MA, USA)
Thermo Fisher Scientific (Waltham,
MA, USA)
Thermo Fisher Scientific (Waltham,
MA, USA)
Thermo Fisher Scientific (Waltham,
MA, USA)
Thermo Fisher Scientific (Waltham,
MA, USA)
Thermo Fisher Scientific (Waltham,
MA, USA)
Sigma Aldrich (St. Louis, MO, USA)
Thermo Fisher Scientific (Waltham,
MA, USA)
Thermo Fisher Scientific (Waltham,
MA, USA)
MilliporeSigma (Burlington, MA, USA)
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Sucrose
SuperSignal West Pico Chemiluminescent
Substrate
Tetraethylammonium chloride (TEA-Cl)
Thiourea
Tris-buffered Saline (TBS)
Tween20

Thermo Fisher Scientific (Waltham,
MA, USA)
Thermo Fisher Scientific (Waltham,
MA, USA)
Thermo Fisher Scientific (Waltham,
MA, USA)
Thermo Fisher Scientific (Waltham,
MA, USA)
Thermo Fisher Scientific (Waltham,
MA, USA)
Thermo Fisher Scientific (Waltham,
MA, USA)

Buffers and Solutions
Name

Composition
0.75 g BSA

Antibody Solution (Western and Dot blots)

50 mL TBS-T
124 mM NaCl
2.5 mM KCl
1.25 mM NaH2PO4

Artificial Cerebrospinal Fluid (ACSF)

24 mM NaHCO2
12.5 mM Glucose
2 mM CaCl2
2 mM MgSO4
5 g Nonfat Powdered Milk

Blocking Solution (Western and Dot blots)
Mass Spectrometry Solvent B

100 mL TBS-T
0.1% Formic Acid in 80% Acetonitrile
92 mM NMDG
2.5 mM KCl
1.25 mM NaH2PO4

NMDG-based ACSF

30 mM NaHCO2
20 mM HEPES
0.5 mM CaCl2
10 mM MgSO4
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2 mM Thiourea
5 mM L-ascorbic acid
3 mM Na-pyruvate
120 mM Cs-methanesolfonate
10 mM HEPES
8 mM TEA-Cl
Patch Pipette Solution
(pH = 7.35; osmolality = 282 mOsm)

5 mM ATP-Mg
0.5 mM GTP-Na
5 mM Phosphocreatine
0.5 mM EGTA
320 mM Sucrose

SV Homogenization Buffer

4 mM HEPES
Protease Inhibitor Tablet
900 mL deionized water

TBS-T

100 mL 10X TBS
1 mL Tween20
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Methods
Animals
Male and female Sprague Dawley rats were obtained from Charles River
Laboratories Inc. (Wilmington, MA, USA) and group housed in a 12-h light–dark cycle and
fed ad libitum. All procedures and protocols were approved by the Institutional Animal
Care and Use Committee of the University of Nebraska Medical Center and conducted in
accordance with the National Institutes of Health Guide for the Care and Use of Laboratory
Animals.

Oxycodone Treatment
The development of the IUO treatment paradigm was adapted from a previously
published study,182 and the overall treatment paradigm previously established in our lab
was followed.185 A schematic of the treatment regimen can be found in Figure 5. Briefly,
nulliparous female (64–70 days of age) Sprague Dawley rats were treated with oxycodone
HCl dissolved in saline or saline vehicle via oral gavage. An ascending dosing procedure
was used wherein doses of 10 mg/kg/day of oxy were orally-gavaged for 5 days followed
by a 0.5-mg/kg/day escalation for 10 days until reaching a final dose of 15 mg/kg/day,
after which females were mated with proven male breeders. The treatment regimen
continued throughout mating, gestation, and parturition until weaning (P21). Because the
half-life of oxy is relatively short and drug distribution can be altered by pregnancy, dams
were monitored daily for signs of opiate withdrawal such as weight loss, diarrhea, and
irritability throughout gestation. For the PNO paradigm, dams were orally-gavaged with 15
mg/kg/day of oxy only after parturition until weaning. Upon weaning of the pups, dams
were euthanized by isoflurane overdose followed by decapitation using a guillotine. To
elucidate intergenerational effects in the IUO and PNO groups, untreated F1 females
(P70) from each condition were mated with male breeders naïve to the experiment. F2

43

pups were housed with their mothers until weaning (P21). All data presented are from
complete litters per condition and include both male and female offspring.
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Figure 5. Schematic of dosing procedure for IUO and PNO dams and oxy exposure of F1
(red star) and F2 (blue star) generations. The intergenerational effects of oxy exposure
resulting from in utero, germline, or breastmilk exposure are studied in the F1 and F2
generations.

45

MRI/MRS Acquisitions (Chapter One)
Basis Set
For these experiments, P17 and P30 F1 pups were used for in vivo localized 1HMRS. Animals were set in a plastic holder and anesthetized by inhalation of 1-1.5%
isoflurane in 100% oxygen and maintained 40-80 breaths/minute. The duration of a study
for a single animal was about 1 h. MRI and MRS data were obtained using a Bruker®
Biospin 7 Tesla/21 cm small animal scanner (Bruker, Billerica, MA), operating at 300.41
MHz, using a laboratory-built 22 mm diameter quadrature birdcage volume coil. All ﬁrst
and second-order shim terms were first automatically adjusted in the volume of interest
(VOI) using MAPSHIM® (Bruker, Billerica, MA), with a final shim, if necessary, performed
manually to achieve a water line width of 10–15 Hz. The water signal was suppressed by
variable power RF pulses with optimized relaxation delays (VAPOR).201 MR images were
acquired for anatomical reference using a multi-slice rapid acquisition with relaxation
enhancement (RARE) sequence (Effective TE = 36 ms, Rare Factor = 8, TR = 4200 ms,
Number of Averages = 2, Scan Time = 3m21s; FOV = 20x20 mm2, Matrix Size = 256x256,
Spatial Resolution = 0.078125 x 0.078125 mm2, Number of Slices = 29, Slice Thickness
= 0.5 mm). 1H-MRS data sets were obtained using semiLASER localization with timing
parameters (TE/TR = 40/4000 ms, 576 averages, 2048 points) from a 2x5.187x1.557 mm3
(16.15 μl) VOI located in the hippocampus. Pulse types and specifications: Excitation:
hermite 90˚, duration = 0.7 ms, bandwidth = 5400 Hz; 1st & 2nd Refocusing: hyperbolic
secant, duration = 4 ms, bandwidth = 9484.5 Hz. The acquisition time was 38:24 min per
data set. All pulses were applied with a frequency offset of -600 Hz to center the pulse
bandwidth between Creatine and NAA. For the water suppression module, the spoiler
strength matrix was calculated automatically. Spoiler strength was 35% and spoiler
duration was 1.5 ms. For each experiment, one data set was acquired without water
suppression to be used as the water concentration reference for the quantitation process.
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Unsuppressed water spectra were obtained with identical metabolite spectra parameters
except for the following: TR = 1s, number of averages (NA) = 1, and Receiver Gain = 64.
One 64-average (for quality assessment) plus four 128-average data sets were acquired
for metabolite measurements using a combination of variable power RF pulses with
optimized relaxation delays (VAPOR)201 scheme for water suppression.
Model parameters and constraints for quantification were generated using spectra
from phantoms (n = 14) for the following metabolites: Alanine (ALA), Aspartate (ASP),
Creatine (CRE), Gamma-Aminobutyric acid (GABA), Glucose (GLC), Glutamine (GLN),
Glutamate (GLU), Glycine (GLY), Lactate (LAC), Myo-inositol (MYO), N-Acetyl Aspartate
(NAA), Phosphorylcholine (PC), Taurine (TAU), and total choline (tCHO). Phantoms of
each metabolite were prepared in pH 7.5 phosphate buffer (100 mM) and contained 3(trimethylsilyl)-1-propane-sulfonic acid and sodium formate as chemical shift and phasing
references. Spectra for each metabolite at known concentrations were acquired using
semiLASER202 sequences at 40 ms TE, maintaining the phantom at 38 °C with a
circulating water jacket during spectral acquisition. The set of metabolites spectra form
what is called a metabolite basis set, which was used as prior-knowledge in the
quantification process. In all groups, n = 6 for all metabolites except LAC (IUO n = 4).
All MRS data were processed and quantified using LCModel (LCMODEL Inc.,
CA).203 All pre-processing was done automatically using a home-built software
programmed in Matlab (MathWorks, Natick, MA). fid(s) signals were first transformed to
the frequency domain using Fourier Transformation and spectra of the signals were
obtained. Then, a truncation operation was used to remove the first 68 points of the fid
that correspond to zero data introduced by the digital electronics of the system before the
meaningful data stream. This was followed by a zero filling operation to add back 68 zerovalue points at the end of the fid in order to maintain the signal with the 2,048 original
number of points. Then, a 5-Hz apodization operation was applied in order to reduce noise
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and truncation artifacts. All spectra were then zero-order phased and first-order phased
using a time of -0.226 ms. Finally, the fid(s) from the water-unsuppressed acquisitions
were corrected for frequency shifts using the NAA peak from the basis sets as reference
and then summed for the metabolite concentration measurement. Metabolite spectra from
phantoms were amplitude-normalized and corrected for frequency shifts using the
reference peaks 3-(trimethylsilyl)-1-propane-sulfonic acid and sodium formate. Residual
water was then removed using the HLSVD filter in the Java-based magnetic resonance
user’s interface (jMRUI) package.204 Finally, the resulting metabolites spectra were made
into a metabolite basis set file and used as prior knowledge for the quantitation algorithms
in LCModel. The water-unsuppressed “water” spectra and the water-suppressed
“metabolite” spectra were then submitted to LCModel for quantitation. Concentration
values of individual metabolites were output in spreadsheet for statistical analysis.

Electrophysiology (Chapter One)
Coronal hippocampal brain slices were prepared from F1 P17 pups (n = 6) using
the “protected recovery” method.205 Briefly, rats were euthanized by CO2 asphyxiation and
decapitation, and brains were rapidly dissected into a slush of artificial cerebrospinal fluid
(ACSF) and continuously bubbled with a mixture of 5% CO2 and 95% O2. The cerebellum
was removed with a razor blade, and the brain was affixed to the cutting chamber using
cyanoacrylate glue. 250-micron-thick coronal brain sections through the hippocampus
were cut using a vibrating microtome (Leica VT1000S) and hemisected into right and left
halves through the midline before being transferred to a net submerged in an N-methylD-glucamine (NMDG)-based ACSF, warmed to approximately 30 °C and bubbled with 5%
CO2 and 95% O2. After a 10- to 15-minute incubation in the NMDG ACSF, slices were
transferred to a chamber containing room temperature ACSF and allowed to recover for
one hour before beginning patch clamp experiments.
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For whole-cell recording, slices were positioned in a recording chamber on an
upright fixed-stage microscope (Olympus BX51WI) and superfused by a gravity-fed
system with ACSF warmed to 29-31 °C using an in-line solution heater at approximately
4 mL/min. The ACSF was supplemented with 60 µM picrotoxin. A concentric bipolar
stimulating electrode was positioned in the stratum radiatum to stimulate Schaffer
collateral axons using a 0.1 ms current delivered at 0.1 Hz from an isolated pulse
stimulator (A-M Systems Model 2100). CA1 pyramidal neurons were targeted for wholecell recording with patch pipettes pulled from thin-walled borosolicate glass on a Sutter P1000 micropipette puller. The patch pipettes had a resistance of 5-8 MΩ when filled with
solution (materials table). Reported voltages were corrected for a 10 mV liquid junction
potential. The intensity-response profile of the evoked excitatory post-synaptic currents
(EPSCs) for each cell was determined by the average of 3-10 responses obtained at each
stimulus strength (50-225 µA). The AMPA/NMDA ratio was measured as the ratio of the
peak of the inward EPSC recorded at -70 mV to the outward EPSC amplitude at 50 ms
post-stimulus at a holding potential of +40 mV. Miniature EPSCs (mEPSCs) were recorded
in the absence of a stimulus and were detected and analyzed using MiniAnalysis
(Synaptosoft). mEPSC frequency for each recorded cell was determined as the median of
the instantaneous frequencies of all detected events for that cell. Due to variability in the
number of cells patched and recorded, respective samples sizes are provided in Figures
8 and 9.

Total RNA extraction, Quality control, library preparation, small RNA-Seq
F1 P14 PFC (Chapter One)
Total RNA from prefrontal cortex (PFC) tissue was isolated from the randomly
selected pups (n = 6) from each treatment group at P14 using the Direct-Zol RNA kit (Zymo
Research, CA, USA) based on the manufacturer’s protocol. Samples were sent to
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UNMC’s Next Generation Sequencing (NGS) core. RNA-seq libraries were generated
beginning with 1 µg of total RNA from each sample using the TruSeq V2 RNA sequencing
library kit from Illumina following recommended procedures (Illumina Inc., San Diego, CA).
Resultant libraries were assessed for size of insert by analysis of an aliquot of each library
on a BioAnalyzer instrument (Agilent Technologies, Santa Clara, CA). Each library
contained a unique indexing identifier barcode allowing the individual libraries to be
multiplexed together for efficient sequencing. Multiplexed libraries (18 samples per pool)
were sequenced on a single flow cell of the NextSeq550 DNA Analyzer (Illumina) to
generate a total of approximately 28 million 75-bp single reads for each sample.
F1 and F2 P14 NAc (Chapter Three)
Total RNA from nucleus accumbens (NAc) tissue was isolated from the randomly
selected male or female pups of each treatment group at P14 using the Direct-Zol RNA
kit (Zymo Research, CA, USA). RNA samples were sent on dry ice to LC Sciences
(Houston, TX, USA) for sequencing. Transcriptomes from all samples were merged to
reconstruct a comprehensive transcriptome using a proprietary Perl script of LC Sciences
(Houston, Texas, U.S.A.). Following transcriptome reconstruction, FPKM (Fragments Per
Kilobase Million) reads were evaluated by StringTie, and differentially expressed genes
(DEGs) were evaluated by edgeR. Potential hits having ±1.5 fold expression and p < 0.05
were validated using relevant TaqMan probes by real-time PCR (RT-PCR). Further
analysis into the Hcrt system was similarly done using RT-PCR TaqMan probes. Deltadelta Ct method206 was used to calculate fold change and statistical significance.

Bioinformatic Analyses (Chapters One, Two, and Three)
In Chapter One, differentially expressed genes (up- and down-regulated) between
SAL and PNO, SAL and IUO, and PNO and IUO were chosen for further functional
characterization using ClueGO plug-in module207 in Cytoscape software.208 The ‘biological
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process’ option in Clue-Go analysis was used to visualize the categories of DEG functions
in each comparison. In Chapter Two, proteins were identified as differentially expressed if
the FDR-corrected P-value was ≤ 0.05 and log2 fold change was ≥ 2. Heatmaps of the top
25 proteins in each comparison were plotted using the function heatmap.2 in the R
(version 3.6.0) package gplots. Gene Ontology (GO) analysis of differentially expressed
proteins were performed using the Cytoscape plugin ClueGO.207 Biological process,
molecular function, and KEGG pathways were included for GO enrichment analysis.
Enriched disease-associated pathways were identified using the Ingenuity Pathway
Analysis (IPA) software (Ingenuity® Systems, CA, USA, www.ingenuity.com). Canonical
pathway analysis in IPA was performed by comparing the differentially expressed proteins
against known canonical pathways (signaling and metabolic) within the IPA database. In
Chapter Three, functional relevance of DEGs (up- and down-regulated) was evaluated
using the Cytoscape plug-in ClueGO.207 A kappa score level threshold of 0.4 was used to
restrict the GO network connectivity with three as minimum and eight as maximum level
of the genes in each GO term.

Synaptic Vesicle Isolation (Chapter Two)
To investigate the effects of in utero and post-natal oxy exposure on synaptic
transmission, we isolated synaptic vesicles (SVs) following the protocol designed by
Ahmed et al.,209 with minor modifications. Briefly, one hemisphere of P14 rat brains (~500
mg) from each group (n = 6) was homogenized in 9 ml of ice-cold homogenization buffer
using a tight-fitting glass-Teflon homogenizer with ten strokes at 2k – 3k RPM. 100 µl of
homogenate was saved for use in western blot. The homogenized mixture was centrifuged
at 2,700 RPM (1,000 g) for 11 min at 4 °C, and the pellet (P1; cell fragments and nuclei)
was discarded. The supernatant was centrifuged at 11,000 RPM (15,000 g) for 16 min at
4 °C. The resulting supernatant (S2) was collected in a 15-ml tube. The pellet (P2;
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synaptosomes) was washed carefully in 1 ml of homogenization buffer, leaving the brown
center of the pellet (mitochondria) remaining on the tube. 100 µl of P2 was saved for use
in western blot. The resuspended P2 was transferred to a tight-fitting glass-Teflon
homogenizer, and 9 ml of ice-cold double distilled water was added to perform osmotic
lysis. Osmotic lysis was accomplished by performing three strokes at 2,500 RPM. 50 µl of
1 M HEPES and protease inhibitors were added immediately after the last stroke. The
osmotic lysis product was centrifuged at 12,000 RPM (17,000 g) for 19 min at 4 °C in a
swinging Ti41 ultracentrifuge rotor. The resulting supernatant (LS1) was combined with
S2. The LS1/S2 mixture was centrifuged at 20,000 RPM (48,000 g) for 29 min at 4 °C in
a swinging Ti41 ultracentrifuge rotor. The resulting supernatant (CS1) was transferred to
a tight-fitting glass-Teflon homogenizer and homogenized using 3 – 5 strokes at 2k – 3k
RPM. To ensure disruption of SV clusters, the homogenized CS1 was drawn through a
20-gauge hypodermic needle attached to a 10-ml syringe and expelled through a 27gauge needle. 5 ml of CS1 was carefully layered onto a 5.5-ml 0.7 M sucrose cushion and
centrifuged at 38,000 RPM (133,000 g) for 1 hour at 4 °C in a swinging Ti41 ultracentrifuge
rotor.
After centrifugation, 350-µl fractions were collected, starting from the top of the
gradient, resulting in 30 350-µl fractions. The white pellet at the bottom of the gradient was
resuspended in 200 µl of homogenization buffer. 50 µl of each fraction and the
resuspended pellet were collected for use in dot blot. The remaining resuspended pellet
was homogenized using a handheld homogenizer. Fractions 16 – 30 and the pellet were
combined and centrifuged at 245,000 g for 2 h and 35 min at 4 °C in a swinging Ti41
ultracentrifuge rotor. These fractions were used based on purity verification using dot
blotting. The supernatant was discarded, and the pellet was resuspended in 200 µl of 1x
PBS. The ultracentrifugation tube was washed again with 100 µl of 1x PBS to ensure
complete reconstitution of the pellet. The resuspended SVs were drawn through a 27-
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gauge hypodermic needle attached to a 1-ml syringe and expelled. 100 µl of the SV was
saved for western blotting. SVs were stored at -80 °C. Protein quantification of the isolated
SVs was carried out using Pierce BCA protein assay (Thermo Scientific, IL, USA). A
schematic of the SV isolation process can be found in Figure 6.
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Figure 6. Schematic of synaptic vesicle isolation adapted from Ahmed et al.209
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Dot Blot (Chapter Two)
To ensure the purity of the isolated SVs, 2 µl of each of the 30 separated fractions
and the pellet from the SV isolation were blotted onto a nitrocellulose membrane
separated into grids. Samples were added slowly so the area of the absorbed drop of
sample was 2 – 4 mm in diameter. The membrane was allowed to dry before blocking
non-specific sites using 5% BSA in TBS-T for 30 minutes to 1 hour. The membrane was
incubated with primary antibody diluted in 0.1% BSA in TBS-T for 30 min at room
temperature. Anti-PSMC6, a proteasome marker, was used to determine fraction purity
and ensure no fractions with proteasome contaminants continued into the sucrose cushion
step of the isolation protocol. After incubation, the membranes were washed three times
with TBS-T for 5 min each. The secondary antibody was diluted according to the
manufacturer’s protocol in 0.1% BSA in TBS-T and added to the membrane for 30 min at
room temperature. Secondary antibodies were HRP-conjugated anti-rabbit IgG. The
membrane was washed three times with TBS-T for 5 min each. Membranes were allowed
to sit in SuperSignal West Pico Chemiluminescent Substrate for 1 min before imaging with
the Azure cSeries Imager (Azure Biosystems, CA, USA).

Western Blot (Chapter Two)
SVs (10 – 20 µg) from each animal were loaded into 4–12% Bis-Tris wells
(Invitrogen, MD, USA) under reducing conditions, followed by transfer to a nitrocellulose
membrane using iBlot2 (Invitrogen) and immunodetection. Nonfat milk (5%) was used to
block nonspecific antibody binding. After blocking, membranes were incubated overnight
at 4 °C with primary antibody. Primary antibodies included GAPDH, PSD95, SYP,
VGLUT1, and SNAP25. MEGF8 and LAMTOR4 were additionally selected from the
proteomic analysis for post-validation. Secondary antibodies were HRP-conjugated antirabbit IgG and HRP-conjugated anti-mouse IgG. Blots were developed using Azure
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cSeries Imager (Azure Biosystems, CA, USA)

with SuperSignal West Pico

Chemiluminescent Substrate.

Mass Spectrometry (Chapter Two)
50 µg of SV protein per sample (n = 6) per group was taken and detergent was
removed by chloroform/methanol extraction. The protein pellet was re-suspended in 100
mM ammonium bicarbonate and digested with MS-grade trypsin overnight at 37 °C.
Peptides cleaned with PepClean C18 spin columns (Thermo Scientific) were resuspended in 2% acetonitrile (ACN) and 0.1% formic acid (FA), and 500 ng of each sample
was loaded onto trap column Acclaim PepMap 100 75 µm x 2 cm C18 LC Columns
(Thermo Scientific) at a flow rate of 4 µl/min, then separated with a Thermo RSLC Ultimate
3000 (Thermo Scientific) on a Thermo Easy-Spray PepMap RSLC C18 75 µm x 50cm C18 2 µm column (Thermo Scientific) with a step gradient of 4–25% solvent B from 10 –
130 min and 25 –45% solvent B for 130 – 145 min at 300 nL/min and 50 °C with a 180min total run time. Eluted peptides were analyzed by a Thermo Orbitrap Fusion Lumos
Tribrid (Thermo Scientific) mass spectrometer in a data-dependent acquisition mode. A
survey full scan MS (from m/z 350–1800) was acquired in the Orbitrap with a resolution of
120,000. The AGC target for MS1 was set as 4 × 105 and ion filling time set as 100 ms.
The most intense ions with charge state 2 – 6 were isolated in 3-sec cycle and fragmented
using HCD fragmentation with 40% normalized collision energy and detected at a mass
resolution of 30,000 at 200 m/z. The AGC target for MS/MS was set as 5 × 104 and ion
filling time set at 60 ms; dynamic exclusion was set for 30 s with a 10-ppm mass window.
Protein identification was performed by searching MS/MS data against the Swiss-Prot
Rattus norvegicus protein database downloaded in May, 2019, using the in-house mascot
2.6.2 (Matrix Science, MA, USA) search engine. The search was set up for full tryptic
peptides with a maximum of two missed cleavage sites. Acetylation of protein N-terminus
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and

oxidized

methionine

were

included

as

variable

modifications

and

carbamidomethylation of cysteine was set as fixed modification. The precursor mass
tolerance threshold was set at 10 ppm and maximum fragment mass error was 0.02 Da.
The significance threshold of the ion score was calculated based on a false discovery rate
(FDR) of ≤ 1%. Qualitative analysis was performed using progenesis QI proteomics 4.1
(Nonlinear Dynamics, MA, USA).

Phenotypic Measurements (Chapter Three)
Body measurements included weight, body length, and head size circumference
and were obtained from the complete litters at P1, P7, P14, and P30. Body mass index
(BMI) and Lee’s Obesity Index (LOI) were calculated as described by Novelli et al.210

Behavioral Studies
Von Frey (Chapter One)
Von Frey experiments were conducted (n = 4) from each group at P17, and the
same animals were tested at P75. The test was commenced as the rats placed four paws
comfortably on the mesh floor and the plantar were clearly visible. The examiner randomly
picked the left or right hind paw as the first evaluated paw during each assessment. A
monofilament Von Frey hair was applied exactly vertical on the plantar surface until the
hair buckled and the shape of the hair was held for 5 s. The specific value of the forces
chosen were: 0.6, 1.0, 1.4, 2.0, 4.0, 6.0, 8.0, 10.0 and 15.0 g. The cut-off force was set as
15.0 g because the paw would be lifted if the next force (26.0 g) was applied. During the
measuring process, each force was applied 10 times with an interval of at least 5 s to allow
the animal to recover from the previous stimuli. Noxious responses were determined if any
of the following robust reflex responses occurred: paw retracting, paw withdrawal, or paw
licking. Once there were 4 positive responses in 10 applications, the force was determined
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as the mechanical withdrawal threshold. The mechanical withdrawal threshold for both of
two paws was recorded.
Social Testing (Chapter Three)
Social testing consisting of social novelty and social preference were carried out
in P60-65 F1 and F2 male and female rats from the different treatment groups using an
in-house built chamber. Briefly, a 90x40x40-cm acrylic chamber was divided into three
30x40x40-cm compartments. Left and right compartments contained 15x15x30-cm
isolation cubes with evenly-drilled holes spaced 1 cm apart along the entirety of the cube.
To evaluate social novelty, a naïve animal of the same sex and of similar age and
size was placed into the left isolation cube. A cagemate of the test animal’s housing cage
was placed into the right isolation cube. The test animal was placed into the central
chamber. For assessing social preference, a new naïve rat (not used in social novelty)
was placed into the left isolation cube, a rubber toy in the right isolation cube, and the test
animal into the central chamber. After 5 min of acclimation, the two doors were lifted and
the test animal was allowed to freely explore the entirety of the social chamber for 15 min.
Animals were then returned to their housing cages, and the social chamber was cleaned
and sterilized.
Scoring for both social tests consisted of the time the animal spent in each
chamber, the number of entries into each chamber, and the number of active contacts
toward one of the isolation cubes. Entry into a chamber was scored if an animal’s head
and all four paws were within the compartment. An active contact was defined as any
attempt to sniff, paw, scratch, touch, or stretch toward any of the isolation cubes when
inside the compartment containing an isolation cube. Testing was recorded, and
recordings were scored manually by scorers blinded to the conditions.
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Marble Burying (Chapter Three)
Marble burying was tested on all three groups on male and female pups between
ages P65-P70. A rat cage (929 cm2, 43.18x21.59x20.32 cm) contained a leveled 5-cm
layer of ¼” corncob bedding (Envigo #7097), and 20 standard glass marbles (15 mm
diameter, 5.2 g) were lightly placed in a 5x4 arrangement along the bedding. The
subject was placed into the cage, and the cage was covered for 30 min. The animal
was removed, and the marbles were imaged and scored by a scorer blinded to the
conditions. A marble was considered buried if more than 2/3 of a marble was under the
bedding.

Data and Statistical Analyses
All data represented in this thesis are reported as mean ± SEM. Data in each
analysis were normally distributed. Significant differences were computed using Welch’s
t-test (Electrophysiology and Western blot) and two-way ANOVA (Von Frey, MRI/MRS
data, social testing) followed by Tukey’s test with a significance criterion of p ≤ 0.05.
Significant intergenerational differences were computed using two-way ANOVA followed
by Tukey’s test with a significance criterion of p ≤ 0.05. Main interactions in
intergenerational studies were further analyzed independently within generations using
one-way ANOVA followed by Tukey’s test with a significance criterion of p ≤ 0.05. Data
were analyzed using the Graph Pad Prism software (La Jolla, CA, USA).
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CHAPTER ONE
A Holistic Systems Approach to Characterize the Impact of Pre- and
Post-natal Oxycodone Exposure on Neurodevelopment and Behavior
Abstract
Increased risk of oxycodone (oxy) dependency during pregnancy has been
associated with altered behaviors and cognitive deficits in exposed offspring. However, a
significant knowledge gap remains regarding the effect of in utero and postnatal exposure
on neurodevelopment and subsequent behavioral outcomes. Using a preclinical rodent
model that mimics oxy exposure in utero (IUO) and postnatally (PNO), we employed an
integrative holistic systems biology approach encompassing proton magnetic resonance
spectroscopy (1H-MRS), electrophysiology, RNA-sequencing, and Von Frey pain testing
to elucidate molecular and behavioral changes in the exposed offspring during early
neurodevelopment as well as adulthood. 1H-MRS studies revealed significant changes in
key brain metabolites in the exposed offspring that were corroborated with changes in
synaptic currents. Transcriptomic analysis employing RNA-sequencing identified
alterations in the expression of key genes associated with synaptic transmission,
neurodevelopment, mood disorders, and addiction in the treatment groups. Furthermore,
Von Frey analysis revealed lower pain thresholds in both exposed groups. Given the
increased use of opiates, understanding the persistent developmental effects of these
drugs on children will delineate potential risks associated with opiate use beyond the direct
effects in pregnant women.
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Introduction
Over the last few years, the increasing trend in opioid abuse has become a major
public health crisis across the globe. As a result, this steep increase in abuse of
prescription opioids, which include both licit and illicit opioids, has resulted in the opioid
epidemic.211 Whilst this epidemic has traversed different groups in the society, pregnant
women are a particularly vulnerable group since they are prescribed opioids such as
morphine, buprenorphine, and methadone, all of which have been shown to cross the
placenta,212-214 potentially impacting the developing fetus. Limited data exist regarding the
effects of in utero (IUO) or postnatal (PNO) exposure to oxycodone (oxy), however. Oxy
is prescribed for multiple types of pain and can bind to mu- and kappa-opioid receptors.215
Oxy easily passes through the blood-brain barrier, thus allowing higher concentrations to
accumulate in the brain,216-218 subsequently contributing to its analgesic properties and
risk for dependency and addiction.
Several studies219 have been conducted with rodent models to investigate the
detrimental effects of gestational opioid use on neurodevelopment of the offspring, but a
gap in knowledge exists regarding the effects of IUO or PNO oxy exposure on
synaptogenesis. We have previously identified novel miRNA signatures related to
neurodevelopment contained within brain-derived extracellular vesicles of PNO and IUO
offspring,185 and our current study aims to investigate metabolic, synaptic, molecular, and
behavioral alterations in these exposed offspring. Using a Sprague Dawley rat model
previously established by our labs,138,185 we employed proton magnetic resonance
spectroscopy (1H-MRS) to measure biochemical changes of main brain metabolites in the
hippocampus. Additionally, we identified synaptic alterations in the hippocampus through
the use of electrophysiology experiments. Further, RNA-sequencing (RNA-seq) was
conducted on tissue RNA isolated from the prefrontal cortex (PFC) to determine changes
in gene expression, particularly in genes related to neurodevelopment, disease states,
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and mood disorders. The hippocampus and the PFC are key regions involved in
substance abuse disorders and the negative emotional state associated with
withdrawal;220 indeed, systemic opioid exposure has been shown to attenuate
hippocampal afferent-driven activity in the PFC.221 For these reasons, we have
investigated both regions in this study to identify alterations in either area of the brain
during the early developmental period spanning from post-natal day 14 (P14) to P17,
which corresponds with peak synaptogenesis.222 In our final experiments, we employed
Von Frey tests to elucidate any lasting impacts of early-life oxy exposure on pain
thresholds. The comprehensive and systematic approach used in this study allows for
thorough research into pre- and post-natal oxy abuse, a critical step in closing the
knowledge gap surrounding this commonly used opioid analgesic.

Results
Quantitation of metabolites in oxy-exposed pups
Brain metabolites are spatiotemporally regulated during development.223 However,
it is unknown whether IUO or PNO exposure influences the expression levels of these
metabolites in the offspring. Accordingly, we conducted 1H-MRS scans on the brain
hippocampus of P17 and P30 saline, PNO, and IUO groups (Figure 7). We found that IUO
or PNO treatment did affect metabolite concentrations in these animals (Metabolite: F(13,
208)

= 96.75, P < 0.0001; Treatment: F(2, 208) = 5.520, P = 0.0046; Interaction: F(26, 208) =

2.093, P = 0.0023). Specifically, we identified higher levels of neurotransmitter aspartate
(ASP) and glutamate (GLU) in both PNO and IUO groups. However, N-acetyl aspartate
(NAA), the second most abundant metabolite in the brain, was significantly elevated in the
IUO group. Additionally, taurine (TAU) concentration was elevated in the PNO group but
was significantly lower in the IUO offspring compared to controls. At P30, 1H-MRS scans
revealed that both PNO and IUO groups had lower levels of NAA than controls, and IUO
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levels were lower than those of PNO, similar to when they were measured at P17
(Metabolite: F(13,

194)

= 101.5, P < 0.0001; Treatment: F(2,

194)

= 3.746, P = 0.0253;

Interaction: F(26, 194) = 2.710, P < 0.0001). Intriguingly, TAU levels were higher in the IUO
group compared to both PNO and control groups (Fig 2B). Together, these data point to
alterations in key metabolite levels in both the PNO and IUO groups that are more
pronounced in the latter.
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B

Figure 7. Metabolite concentrations in the brain measured by 1H-MRS at P17 and P30 in
PNO and IUO animals. Measured metabolites included Alanine (ALA), Aspartate (ASP),
Creatine (CRE), Gamma-Aminobutyric acid (GABA), Glucose (GLC), Glutamine (GLN),
Glutamate (GLU), Glycine (GLY), Lactate (LAC), Myo-inositol (MYO), N-Acetyl Aspartate
(NAA), Phosphorylcholine (PC), Taurine (TAU), and total choline (tCHO). A) In all groups
at P17, n = 6 for all metabolites except Lac (n = 4 in the IUO group). IUO animals showed
higher concentrations of Asp, Glu, and NAA compared to controls. IUO had a lower
concentration of Tau than controls. B) For all groups at P30, n = 6 except GABA (IUO n =
5), GLU (SAL n = 5), and GLY (SAL n = 5). For P30 ALA, n = 3 for each group except IUO
(n = 5). For LAC, n = 4 for each group. IUO and PNO had lower concentrations of NAA,
and IUO offspring had a higher concentration of Tau compared to control and PNO
animals. * p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001.
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Synaptic alterations in IUO and PNO offspring
CA1 synapses were monitored in hippocampal slices of control, PNO, and IUO
rats (Figures 8 and 9). Input-response curves showed that the post-synaptic currents in
the PNO group cells were smaller than control (p = 0.02, p = 0.017; Figure 8). Although
the AMPA/NMDA ratio in PNO rats appeared reduced compared to controls, the difference
was not significant (p = 0.07; Figure 8). The paired pulse ratio (PPR) of post-synaptic
currents did not significantly differ among the three groups, suggesting no change in
presynaptic vesicle release probability (Figure 8). When measuring miniature excitatory
post-synaptic currents (mEPSCs), we found that, although the frequency and amplitude
of the currents did not differ between groups, the PNO mEPSCs had slightly faster decay
kinetics (p = 0.0048; Figure 9), which is consistent with altered AMPA receptor subunit
composition. Together, these data point to altered synaptic maturation in the PNO
offspring.
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Figure 8. Evoked EPSC monitored in hippocampal slices of control, PNO, and IUO rats.
Evoked EPSC data; Top: A series of EPSCs recorded in each of the three treatment
conditions in response to a series of stimulus strengths (50-225 A). Stimulus timing is
marked above the traces. Group data show the intensity-response profiles for cells
recorded from Saline, PNO, and IUO rats. Middle: AMPA receptor and NMDA receptormediated EPSCs recorded by voltage-clamping CA1 pyramidal cells at -70 and +40 mV,
respectively. The AMPA receptor component was measured at the peak of the inward
EPSC while the NMDA receptor component was measured 50 ms post-stimulus. Group
data of AMPA/NMDA ratios show there was no significant difference between the groups.
Bottom: Paired pulse traces showing the characteristic synaptic facilitation in response to
a pair of pulses separated by 50 ms. Group data show the paired pulse ratio was not
significantly different between treatment conditions. Sample sizes of recorded cells are
shown in the bars of each graph; all data represented as mean ± SEM.
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Figure 9. mEPSC monitored in hippocampal slices of control, PNO, and IUO rats. Traces
of mEPSCs recorded in the absence of stimulation followed by mEPSCs waveforms from
individual cells. These were obtained by averaging all detected events in individual cells.
Group data show that mEPSC amplitudes and frequencies were not significantly different
between treatment groups. Group data of mEPSC decay time constants (decay), show that
mEPSCs in the PNO group decayed more quickly than in control. Sample sizes of
recorded cells are shown in the bars of each graph; all data represented as mean ± SEM.
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RNA-seq highlights gene expression changes in oxy-exposed pups
To further understand the molecular causes associated with changes in synaptic
currents, we performed RNA-seq analysis on the PFC (Figure 10A). Employing a criteria
of 1.5 fold change and p < 0.05, we found 62 genes (20 up and 42 down) between saline
and PNO and 161 genes (78 up and 83 down) between saline and IUO. When comparing
the PNO and IUO groups, we found 1,465 genes (1,199 up and 266 down). We found
three genes (Sytl2 – Synaptotagmin-like 2, Vwa5b1 – Von Willebrand Factor A DomainContaining Protein 5B1, and a predicted gene AABR07042623.1) were differentially
regulated among all three groups.
Next, the enriched biological pathways associated with these differentially
expressed proteins were determined using Clue-GO analysis (Figure 10B). Notably,
pathways involved in synaptic transmission and morphine, nicotine, and alcohol addictions
were significantly enriched in the two treatment groups. Furthermore, the opioid signaling
pathway was affected in the PNO and IUO offspring. A number of the genes affected in
the IUO and PNO pups were associated with diseases and psychotic disorders (Table 1).
To summarize, oxy exposure can significantly affect neurodevelopment in exposed
offspring by inducing changes in key genes and pathways during synaptogenesis that
could persist during late adolescence and adulthood.
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Figure 10. Differentially expressed genes at P14 identified using RNA-Seq. RNA was
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isolated from the PFC regions of P14 brains (n = 6) for each group. Mapping of biological
processes in the PFC. Clue-Go pie diagrams resulting from RNA-seq data show enriched
biological processes involved in developmental, neurological, and psychological
disorders, which are more impacted in the IUO offspring. The asterisks represent the
group term p-value representing each category. * p < 0.05, ** p < 0.01.
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Table 1. Differentially expressed genes identified in PFC from both IUO and PNO
groups that are related to diseases or psychotic disorders. A criterion of ±1.5 fold
change, p < 0.05, and FDR < 5% was used.
Disease or Psychotic
Disorder

Genes Associated with the Disorder

Alcohol-related birth defect

NTRK2

Alcohol withdrawal syndrome

GAD2

Anhedonia

OPRK1, PDYN

Cannabis dependence

GABRA2

Chronic schizophrenia

CYP3A4

Clinical depression

ITGAL, NPY

Cocaine dependence

OPRK1, PDYN, DRD3, GABRA2, OPRM1, NPY

Delirium

DRD3

Depression, postpartum

OPRM1

Dysphoric mood

PDYN, OPRM1

Dysthymic disorder

NTRK2

Fetal alcohol spectrum
disorders

BCL2

Susceptibility to
schizophrenia

MYH9, PLP1

Manic symptom

DNAH8, NR3C2, CSRP1

Non-organic psychosis

OPRM1, TBX1, CDH17, PDE10A, CSNK1E, DLX1,
SP8, SP3

Paranoid schizophrenia

NTRK2

Psychoses, drug

DPYSL2, DRD1

Recurrent depression

DRD1, DRD3

Schizoaffective disorder

GRIA1, NPY, PCDH11Y, GABRB1

Schizophrenia, catatonic

CELSR1

Seasonal affective disorder

HTR2C, PER3, NPY, RORA

Severe depression

ESR2

Wernicke-Korsakoff
syndrome

ALDH2
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Pain sensitivity in oxy-exposed pups
One key pathway we identified from our RNA-Seq analysis was regulation of
sensory perception of pain. Because oxy is prescribed for pain management, we
investigated whether PNO or IUO exposure has lasting effects on pain sensitivity. Von
Frey testing was conducted at P17 (pups exposed to oxy via the breastmilk) and on the
same animals at P75 (adulthood) after a sustained absence of oxy exposure (Figure 11).
While no significant differences in the pain threshold were observed in the PNO or IUO
at P17, both groups displayed a significantly lower pain threshold than controls at P75
(Age: F(3, 242) = 455.3, P < 0.0001; Treatment: F(2, 242) = 88.13, P < 0.0001; Interaction:
F(6, 242) = 31.18, P < 0.0001). These data suggest a lasting impact of early life oxy
exposure on pain sensitivity during adulthood.
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Figure 11. Measurement of pain thresholds using the Von Frey test. Animals from each
group (n = 4) were tested at P17 and again at P75 to determine changes in pain
thresholds. At P75, the oxy-exposed groups have lower pain thresholds than controls.
Additionally, IUO pups had lower pain thresholds than PNO pups. All data represented as
mean ± SEM. *** p < 0.001, **** p < 0.0001.
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Discussion
While previous studies have reported poor neurodevelopmental outcomes in
offspring exposed to opioids,180,182,183,224 a comprehensive analysis comparing changes in
neurodevelopment with pre- and post-natal exposure to drugs has not been evaluated. In
the present study we show for the first time a comparative analysis on alterations in
metabolic, synaptic, molecular, and behavioral changes in offspring exposed to the oxy
pre- and post-natally. Additionally, the PNO and IUO groups are clinically relevant.138,185
The dose of oxy (15 mg/kg) used in our study has been shown to be well-tolerated in
animals and mimics the development of chronic analgesia in humans.225,226 Importantly,
the PNO group established by our studies represents neonates in the neonatal intensive
care unit (NICU) that may be exposed to high-dose opiates through infusions. Infants
supported by extracorporeal membrane oxygenation (ECMO) and mechanical ventilation
are exposed to opiates for sedation and analgesia,227 and in some cases these infants
may require support for three weeks or longer, exposing the newborns to potent opiates
for an extended period of time and contributing to the increase in neonatal abstinence
syndrome diagnoses.228,229 Our PNO group provides a high-dose opiate exposure
comparable to the high-dose opiate exposure neonates in the NICU experience, thus
allowing us to fill a gap in knowledge regarding the implications of these opiate drips on
the neurodevelopment of newborns.
The use of both PNO and IUO groups in this study was critical to elucidate the
extent of oxy exposure effects on neonates. While the PNO group was exposed to oxy
only via the breastmilk, the IUO group was exposed via placental concentrations of
oxycodone throughout gestation as well as via the breastmilk. Opiates have been shown
to pass into the placenta and act on fetal opioid receptors.212-214 Oxy as a postoperative
analgesic has been reported in the literature for postpartum pain or caesarian sections in
lieu of morphine drips.230,231 Because both PNO and IUO groups experienced postnatal

74

exposure via the breastmilk, it is important to note that the degree of exposure of an infant
to a drug passed through the breastmilk depends on the concentration of the drug in the
milk, the amount of milk ingested, and the rate of elimination from the infant. 232 A human
study by Seaton et al. has shown that oxycodone is concentrated in the breastmilk, and
offspring exposed via the breastmilk may receive less than 10% of a typical oral
therapeutic infant dose (0.1–0.2 mg/kg).233 Despite this low dose, infant exposure to oxy
via the breastmilk has been associated with sedation and central nervous system
depression,234 and a number of animal studies have also revealed deficits in behavior and
development associated with perinatal opioid exposure.180,182,183,224
The effects of pre- and post-natal oxy use on brain chemistry have not been clearly
elucidated in the literature. Therefore, we used 1H-MRS to investigate the biochemical
changes present in the brains of P17 and P30 rats in the PNO and IUO groups. At P17,
the IUO group had higher signals for ASP and GLU compared to controls and higher
signals of NAA compared to controls and PNO. The IUO group also had lower levels of
TAU than controls. GLU and ASP regulate a majority of the excitatory synaptic
neurotransmission in the brain,235 and their enhanced expression may point to
excitotoxicity and possibly enhanced excitatory signaling in the brain. Additionally, higher
levels of ASP may suggest more ASP is available to react with acetyl-CoA to make NAA,236
which was also elevated in the IUO group at P17. By P30, both PNO and IUO groups had
lower levels of NAA, and IUO had higher levels of TAU than both PNO and saline controls.
In a human study of opiate-dependent individuals, NAA and GLU were present in lower
concentrations in the opioid-using cohort than the controls.237 In our study, we see that the
level of NAA for both PNO and IUO groups is lower at P30 than at P17, and the GLU levels
are not significantly different from the control group. Interestingly, NAA is believed to be
present in neurons and has been used as a measure of neuronal loss or dysfunction.238
Lower levels of NAA have been reported in studies of brain ischaemia,238,239 multiple
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sclerosis,240 and several more neurodegenerative diseases.241 The lower levels of NAA in
both the PNO and IUO at P30 may indicate neuronal damage or loss in synaptic abilities
in these oxy-exposed groups as they age, even without further exposure to oxy.
Intriguingly, a recent study by Ward et al. suggests that NAA may also be a marker of CNS
injury after opioid dependence and withdrawal,242 so the lower concentration of NAA in
PNO and IUO offspring at P30 may also indicate withdrawal. By P30, TAU is present in
higher concentrations in the IUO compared to both PNO and control groups. TAU has a
role in brain development, and TAU deficiency can lead to a delay in cell differentiation
and migration in the cerebellum, pyramidal cells, and visual cortex.243 Hernandez-Benitez
et al. have shown that TAU promotes neural development in the embryonic brain as well
as in adult brain regions,244 so the lower levels of TAU may point to neurodevelopmental
deficits.
Based on the observation of increased GLU levels in our MRS study, we
investigated the extent of synaptic changes in IUO and PNO animals. Glutamate receptors
play a role in mediating the reward pathway involved in drug addiction,245 and they are
also involved in opiate-induced neural and behavioral plasticity.246-248 AMPA receptors,
one type of ionotropic glutamate transporter, are crucial for opioid withdrawal during
development.249-254 While we saw a reduction in the AMPA/NMDA ratio in the PNO rats,
the difference was not significant. Additionally, there were no differences in the pairedpulse ratio of post-synaptic currents, suggesting no changes in vesicle release.
Interestingly, PNO mEPSCs had slightly faster decay kinetics, which is consistent with
altered AMPA receptor subunit composition. Intriguingly, no significant effects were seen
in the IUO group, which is interesting because the IUO pups were exposed to oxy for a
much longer period than PNO pups. Possible reasons include the potential loss of neurons
given the longer exposure to oxy255,256 and the higher glutamate levels in the IUO pups
compared to the PNO group, as evidenced by 1H-MRS. Thus, our study for the first time
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lends insight into the synaptic changes associated with PNO exposure and its effects on
altered glutamatergic signaling.
Recent studies employing high-throughput technologies have further provided new
insights into the molecular underpinnings associated with chronic oxy dependency. These
include alterations in key genes associated with integrated stress response in the brain,257
induction of apoptotic signaling in neurons by promoting demyelination,224 alterations in
reward related genes,258 axon guidance molecules,259 inflammation/immune related
genes,226 neurotransmitter receptor genes260 as well as expression of synaptic plasticity
genes,261 including key sex-specific neuroplasticity-related genes.262 Similarly, our RNAseq data showed alterations in pathways associated with synaptic transmission, axon
guidance, inflammasomes, and genes associated with the reward system. Among others,
genes affecting synaptic transmission and axon development included Egfr, Adrb2, and
Ntrk. Interestingly, Fan et al. found that chronic oxy exposure leads to axonal degeneration
in rat brains.224 Chronic oxy exposure altered the white matter of the rats through
deformation of axonal tracks, reduction of the size of axonal fascicles, loss of myelin basic
protein, and accumulation of amyloid precursor protein.224 Importantly, human studies of
infants prenatally-exposed to opioids have shown alterations in the white matter, such as
punctate white matter lesions or white matter signal abnormalities on structural MR
imaging,263,264 so the results of our RNA-seq align with what is known in the field for both
animal models and human studies. Interestingly, our RNA-seq data also showed
differences in glutamatergic synapse genes, with seven genes being differentially
expressed in the IUO and PNO groups: Adrb2, Egfr, Grik2, Npy2r, Ntrk1, Ntrk2, and Oxtr.
Combined with our electrophysiology results, our RNA-seq results further suggest
alterations in glutamatergic signaling within the reward pathway of these exposed
offspring. In addition, our studies suggest PNO and IUO exposure not only alter gene
expression but also may increase the risk of developing other diseases, particularly renal
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disease. Genes associated with renal adysplasia, renal cancers, renal failure, and several
other renal diseases were differentially regulated in the PNO and IUO groups.
Interestingly, depletion of TAU has been shown to play a role in renal dysfunction. 243 In
human studies, opioid use has been associated with acute kidney injury, particularly in the
case of opioid overdose.265 The altered gene expression and lower levels of TAU in the
reward system of the IUO offspring during early development may warrant further
exploration into the potential of these offspring to develop renal diseases as adults,
particularly because P30 IUO animals had significantly higher levels of TAU than PNO or
controls. Further, several genes in our analysis are also involved in other substance userelated disorders, such as nicotine, cocaine, and cannabis dependence, morphine
addiction, and fetal alcohol spectrum disorders. Opioid use has also been associated with
mental health disorders, with a higher proportion of adolescents exposed prenatally to
opioids having experiences with major depressive episodes, alcohol abuse, and attention
deficit hyperactivity disorder.199 Genes associated with depression, anxiety disorders,
schizophrenia, and obsessive compulsive disorder were all enriched in both PNO and IUO
offspring, suggesting a higher risk for such disorders in these offspring.
Oxy is generally prescribed for pain management, therefore we sought to
determine how pre-/post-natal oxy exposure may affect the pain thresholds in PNO and
IUO animals. When assessed by the Von Frey filament test at P17, the PNO and IUO
pups did not exhibit a difference in pain threshold compared to saline controls. However,
during adulthood (P75), we saw a significantly lower pain threshold in the IUO when
compared to both PNO and saline offspring. The PNO group also had a lower pain
threshold when compared to saline controls. In a study of neonatal morphine exposure,
P40 rats exhibited a lower pain threshold than the controls, but the pain threshold
approached control levels by P50 when tested using Von Frey.266 Because we see similar
results continuing up to P75, pre- and post-natal exposure to oxy may alter normal

78

synaptic development involved in nociception. Indeed, a number of genes shown to be
differentially regulated in both PNO and IUO in our RNA-seq data are associated with
pain, such as Adrb2, Cck, Htr2c, Npy2r, Oprk1, Oprm1, and P2rx3. Further analyses of
these genes could possibly lend more mechanistic insights into the pain etiology in these
offspring.
In summary, our study using a holistic systems approach shows a comparative
analysis on alterations in metabolic, synaptic, molecular, and behavioral changes in
offspring exposed to the prescription opioid oxy pre- and post-natally. Importantly, these
changes not only impact the overall development during early stages but also persist into
adulthood.

79

CHAPTER TWO
Distinct synaptic vesicle signatures associated with pre- and postnatal oxycodone exposure
Abstract
The current opioid crisis ravaging all segments of the society continues to pose a
rising public health concern. Importantly, dependency on prescription opioids such as
oxycodone (oxy) during and after pregnancy can have a significant impact on the overall
brain development of the exposed offspring, particularly at the synapse. A significant
knowledge gap that still remains is the identification of distinct synaptic signatures
associated with these exposed offspring. Accordingly, the overall goal in the current study
was to identify distinct synaptic vesicle (SV) signatures. Using Sprague Dawley rats to
develop an animal model that mimics oxycodone exposure in utero (IUO) and postnatally
(PNO), we employed a quantitative mass spectrometry-based proteomics platform to
examine changes in the synaptic vesicle proteome and associated functional pathways in
postnatal day 14 (P14) offspring. MEGF8, associated with Carpenter syndrome, was
downregulated in the IUO offspring while LAMTOR4, associated with the Ragulator
complex involved in lysosomal signaling and trafficking, was found to be upregulated in
the PNO groups. The respective differential expression of these proteins was further
validated by western blot. Our current study shows that exposure to oxy in utero and
postnatally impacts the SV proteome in the exposed offspring. Moreover, the identification
and validation of key treatment-specific SV markers could further help elucidate their role
in inducing synaptic alterations during brain development in the exposed offspring.
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Introduction
In recent years, widespread abuse of prescription opioids and dramatic increase
in the availability of illicit opioids have created what is known as the opioid epidemic. 211
Pregnant women are a particularly vulnerable group since they are prescribed opioids
such as morphine, buprenorphine, and methadone, all of which have been shown to cross
the placenta,212-214 potentially impacting the developing fetus. Limited data exist regarding
the effects of in utero (IUO) or postnatal (PNO) exposure to oxycodone (oxy), however.
Oxy is prescribed for multiple types of pain and can bind to mu- and kappa-opioid
receptors.215 Oxy also passes through the blood-brain barrier, allowing higher
concentrations of oxy to accumulate in the brain,216-218 which can contribute to the
analgesic properties as well as the risk for dependency and addiction.
Several studies219 have been conducted with rodent models to investigate the
detrimental effects of gestational opioid use on neurodevelopment of the offspring, but a
gap in knowledge exists regarding the effects of IUO or PNO oxy exposure on
synaptogenesis. Addictive drugs, such as opioids, produce significant and persistent
changes in the synapse, which may explain their long-term effects.267 One way in which
to study changes at the synapse is through the use of synaptic vesicles (SVs). SVs, small
vesicles 40-50 nm in diameter, are found in the presynaptic terminal and act as a store for
neurotransmitters.209 Upon arrival of an action potential, SVs docked and primed at the
active zone of the presynaptic plasma membrane fuse with the membrane and release
neurotransmitters into the synaptic cleft, after which the vesicles are retrieved via
endocytosis, thus restoring the presynaptic vesicle pool.268 With around 5% of the total
protein concentration of the mammalian central nervous system being contributed by SVs,
understanding the protein composition of these vesicles and its influence on the trafficking
of SVs is essential in understanding neurotransmitter release.209,268 Mass spectrometry
and proteomic strategies have been used to compare protein expression profiles of parts
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of the synapse, including SVs, to create a coherent map of the synapse proteome.269 Such
analyses of the synaptic proteome are critical in understanding the role of synaptic
proteins in disease states such as drug addiction, as proteomic analysis allows for the
global view of drug-induced changes within a specific proteome. While we have previously
identified novel miRNA signatures related to neurodevelopment contained within brainderived extracellular vesicles of PNO and IUO offspring,185 the present study aims to
further investigate the effect of oxy exposure on the induction of alterations in the synaptic
vesicle (SV) proteome.
Using a pre- and postnatal oxy exposure Sprague Dawley rat model previously
established in our lab,185 we employed a mass spectrometry-based proteomic approach
to examine changes in the SV proteome resulting from in utero and postnatal oxy
exposure. Subsequent pathway analysis of SV signatures highlighted a number of
functional pathways affected by the differential expression of these SV signatures. The
proteomics-based approach used in this study allows for in-depth research into the
changes of SV signatures associated with perinatal oxy exposure. Further, the
identification of associated functional pathways and disease states affected by the protein
expression changes in these vesicles elucidates potential downstream effects that may
continue to affect the development of IUO and PNO offspring.

Results
Purity and validation of synaptic vesicle samples
To ensure sufficient protein content, SVs were isolated from one complete
hemisphere of the brain (~500 mg) removed from IUO, PNO, and control P14 animals. To
verify our product contained only purified SVs, we performed dot blot and western blot
analyses on isolated fractions collected during different stages of our protocol. To ensure
no proteasome contaminants remained in our sample, we conducted a dot blot analysis
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using the proteasome marker anti-PSMC. Of the 30 fractions and the pellet collected from
our protocol, we found the distribution of proteasome contaminants was higher in fractions
1 – 15 compared to fractions 16 – 30 and the pellet (Figure 12A). Thus, only fractions 16
– 30 and the pellet were used for our SV isolation protocol.
Further, we validated the purity of our SVs through western blot analysis. We
compared the expression levels of known synaptic proteins present in the homogenate,
synaptosome (P2), and SV fractions (Figure 12B). Known integral membrane proteins
present on SVs were enriched in the final SV fractions. Proteins not specific to the SV
were enriched in the homogenate and P2 fractions. After validating the purity of our SV
product, samples from each group were for mass spectrometry.

83

Figure 12. SV isolation purity and validation of SV proteins. A) Dot blot depicting SV purity
using the proteasome marker anti-PSMC. B) Western blots further demonstrating the
concentration of synaptic proteins in the purified SVs compared to other collected fractions
(homogenate and P2).
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Differential expression of synaptic vesicle proteins
To examine changes in the SV proteome resulting from in utero and postnatal oxy
exposure, purified SVs were sent for proteomic analysis using quantitative mass
spectrometry. A number of proteins were found to be differentially expressed in both the
IUO and PNO groups when compared to saline controls (Figure 13). A Clue-GO analysis
of the differentially expressed proteins highlighted several pathways that were affected in
the PNO and IUO groups. In the PNO group, cell-cell adhesion, SNARE binding, axon
guidance, vesicle docking, synaptic membrane adhesion, and regulation of axon guidance
were among the biological processes affected by differential expression of SV proteins
(Figure 14A). In the IUO group, glutamate receptor signaling, endosome transport,
regulation of synapse assembly, and vesicular transport were affected (Figure 14B).
Additionally, a number of the differentially expressed proteins were uniquely up- or
down-regulated in the IUO and PNO groups (Figure 15). Of the differentially expressed
proteins in the PNO group compared to controls, 288 were upregulated and 62 were
downregulated. In the IUO group, 205 proteins were upregulated while 25 proteins were
downregulated. Further, of the up-regulated proteins in both PNO and IUO comparisons
with controls, 48 proteins were common. Of the downregulated proteins, three proteins
were common. Furthermore, when comparing the upregulated proteins of the IUO with the
downregulated proteins of the PNO, five proteins were common. When comparing the
upregulated proteins of the PNO with the downregulated proteins of the IUO, only one
protein was common.
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Figure 13. Differential expression of SV proteins isolated from one complete brain
hemisphere of P14 IUO, PNO, and control rats. A) Quantitative mass spectrometry
revealed a number of proteins differentially expressed in PNO groups compared to saline
controls. B) Quantitative mass spectrometry revealed a number of proteins differentially
expressed in IUO groups compared to saline controls.
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Figure 14. Differential expression of SV proteins isolated from one complete brain
hemisphere of P14 IUO, PNO, and control rats. A) ClueGo representations of differentially
expressed proteins in the PNO group compared to control. B) ClueGo representations of
differentially expressed proteins in the IUO group compared to control. Asterisks represent
the group term p-value of each category. *p < 0.01, **p < 0.001.
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Figure 15. Uniquely up- or down-regulated proteins found in each comparison conducted
among the groups.

89

Further, enriched disease-associated pathways were identified using the Ingenuity
Pathway Analysis (IPA) software. Top canonical pathways affected in the PNO group
compared to saline control included the synaptogenesis pathway, clathrin-mediated
endocytosis signaling, Huntington’s Disease signaling, insulin receptor signaling, and
axonal guidance signaling. Additionally, pathways associated with neurological disease,
hereditary disorders, psychological disorders, and skeletal and muscular disorders were
also affected in the PNO group (Figure 16A). Physiological and molecular pathways, such
as those involved in nervous system development and function, behavior, cellular
development and cellular growth and proliferation, were also affected in these animals. A
number of pathways associated with heart failure, liver dysfunction, and renal issues were
also impacted by PNO treatment. In the IUO group, the top canonical pathways that were
affected by oxy exposure included the synaptogenesis pathway, clathrin-mediated
endocytosis signaling, caveolar-mediated endocytosis signaling, and glutathione redox
reactions (Figure 16B). Pathways associated with neurological disease, inflammatory
response, and respiratory disease were among the disease-associated pathways affected
by IUO treatment. Physiological and molecular functions, such as nervous system
development, behavior, and cell-cell signaling, were also found to be affected in the IUO
group. Further, pathways associated with cardiac, liver, and renal abilities were affected
with IUO treatment. Overall, both IUO and PNO animal SV proteomes denoted several
differentially regulated proteins that impact biological pathways, particularly those
associated with several disease states.
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Figure 16. Enriched disease-associated pathways identified using Ingenuity Pathway
Analysis (IPA) software. A) Pathways enriched in the PNO group compared to saline
controls. B) Pathways enriched in the IUO group compared to saline controls.
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Further, the IPA revealed analysis-ready hits that were significantly up- or downregulated in the groups. Of these, MEGF8, which is associated with Carpenter’s
syndrome,270,271 was downregulated in the IUO SVs, and LAMTOR4, a regulator of
microglial lysosomes,272 was upregulated in the PNO SVs. Our western blots validated
these results, showing a lower expression of MEGF8 in IUO SVs and a higher expression
of LAMTOR4 in PNO SVs compared to controls (Figure 17).
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Figure 17. Post-validation of LAMTOR4 and MEGF8 expression in SVs isolated from one
complete brain hemisphere of P14 IUO, PNO, and control rats. A) Validation of LAMTOR4
upregulation in PNO SVs. B) Validation of MEGF8 downregulation in IUO SVs.
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Discussion
Drugs of abuse, such as amphetamine, cocaine, nicotine, and morphine, have
been shown to alter the structure of dendrites and dendritic spines on cells in regions of
the brain associated with reward, judgment, and inhibitory control.267 Robinson et al.
suggested that this structural plasticity associated with exposure to drugs of abuse reflects
a reorganization of patterns of synaptic connectivity that alters their operation, thus
contributing to the detrimental effects drug use, namely addiction.267 Alterations in the
synaptic abilities in one area of the brain may result in strengthening or weakening
connections with other brain regions, possibly driving distinct aspects of addictive
behavior.273 Chronic morphine studies have shown alterations in gene expression,
synapse morphology, synaptic transmission, and synaptic protein profiles,274 but studies
regarding oxy are still lacking. With regard to synaptic plasticity, our lab has previously
shown that the number of dendritic spines decreased with PNO and IUO exposure.185 In
the same study, we identified novel extracellular vesicle signatures associated with PNO
or IUO treatment that may impact synaptogenesis in these offspring. The present study
sought to further this investigation of the impact of PNO and IUO exposure on synaptic
development through the use of synaptic vesicles, identifying novel SV signatures
associated with PNO and IUO exposure. We also found that the differentially expressed
proteins associated with the SVs impact functional pathways as well as disease states.
As mentioned in our previous work, the PNO and IUO groups are clinically relevant, 185
thus lending translational significance to our study.
From the purified SVs isolated from one intact brain hemisphere of P14 PNO and
IUO rat brains, a number of functional pathways and disease states were suggested to be
affected by the differentially regulated protein contents of the SVs. Of the several
pathways impacted by PNO and IUO exposure, axon guidance and axon fasciculation
were particularly interesting. Human studies have shown that prenatal opioid exposure
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can result in abnormal tract development in newborns that persists at 12 to 15 years of
age.264,275 Additionally, infants born with prenatal opioid exposure had alterations in the
white matter, such as punctate white matter lesions or white matter signal abnormalities
on structural MR imaging.263 In preclinical studies, chronic oxy exposure altered the white
matter of rats through deformation of axonal tracks, reduction of the size of axonal
fascicles, loss of myelin basic protein, and accumulation of amyloid precursor protein.224
Proteomic investigations of morphine-regulated changes in the synapse have shown
signaling,

vesicle

trafficking,

cytoskeletal

proteins,

energy

metabolism,

signal

transduction, synaptic transmission, and cell adhesion all to be affected.158,274,276-279 Similar
pathways were shown to be affected in both PNO and IUO groups of our study, specifically
pathways associated with vesicle docking, membrane adhesion, signaling, synapse
assembly, and vesicular transport.
Increasing evidence suggests the opioid system controls a number of aspects
related to the pathophysiology of neurological disorders.280 Opioid use has also been
associated with mental health disorders, with a higher proportion of adolescents exposed
prenatally to opioids having experiences with major depressive episodes, alcohol abuse,
and attention deficit hyperactivity disorder.199 In our PNO group, Huntington’s disease
signaling was affected by oxy exposure. Interestingly, in patients with Huntington’s
disease, individuals who abused substances had a significantly earlier age of motor
onset.281 Additionally, both PNO and IUO exposures were associated with a number of
renal complications. In human studies, opioid use has been associated with acute kidney
injury, particularly in the case of opioid overdose.265 With regard to cardiac diseases, which
were associated with both PNO and IUO groups, a recent study found that coronary artery
disease was significantly higher in patients with opioid use than controls, suggesting opioid
use may be an important risk factory in this disease.282 Further, opiate consumption has
been linked to hypertension and diabetes mellitus, and evidence suggests that chronic
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opioid use may increase the risk of cardiovascular diseases.283 Further, chronic morphine
use was associated with increased risk of both renal and hepatic damage.284 Liver disease
associated with PNO and IUO groups may stem from the metabolism of oxy in the liver.
Verna et al. suggest that the metabolic pathways involved in opioid metabolism may
contribute to or worsen liver injury.285 δ-opioid receptors, which contribute significantly to
cellular development and are abundant in liver tissue, have been shown to affect the
initiation and progression of liver disease.286 Additionally, histopathologic examination of
hepatocytes from rat models of chronic opioid use exhibited sinusoidal dilatation,
perivenular ballooning degeneration extending to the midzonal region, perivenular
necrosis, hemorrhage, and focal microvesicular steatosis.284 Taken together, these results
highlight the importance of understanding the long-term effects of perinatal exposure to
opioids, as a number of complications and disease states have been associated with the
toxic effects of opioids.
The downregulation of MEGF8 and upregulation of LAMTOR4 revealed in our IPA
in the IUO and PNO SVs, respectively, were particularly interesting. MEGF8 is a singlepass type I membrane protein that contains several EGF-like domains.271 Defects in the
gene that encodes MEGF8 result in Carpenter syndrome, which is an autosomal recessive
multiple congenital malformation disorder characterized by multisuture craniosynostosis
and polysyndactyly, umbilical hernia, cryptorchidism, and congenital heart disease.270
Interestingly, loss of MEGF8 disrupts axon guidance in the peripheral nervous system,
leading to limb, heart, and left-right patterning defects.287 As mentioned before, human
newborns with prenatal opioid exposure had alterations in the white matter,263 and
preclinical models of chronic oxy administration have revealed deformation of axonal
tracks, reduction of the size of axonal fascicles, loss of myelin basic protein, and
accumulation of amyloid precursor protein.224 Perhaps the downregulation of MEGF8 may
contribute to these deficits in axonal development reported with prenatal opioid exposure.
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LAMTOR4 is part of the Rag complex, a scaffold protein complex comprised of
LAMTOR subunits 1 – 5 that senses amino acids and lipids and integrates growth factor
signaling.288 This “Ragulator” complex also controls the activity of the mTOR complex 1
(mTORC1) on the lysosome.289 Interestingly, mTORC1 is required for the initiation and
maintenance of chronic pain and opioid-induced tolerance/hyperalgesia.290 Additionally, it
has been suggested that prenatal opioid exposure is the next neonatal inflammatory
disease.291 Intriguingly, LAMTOR4 is essential for microglial development; zebrafish
lacking LAMTOR4 were shown to have a reduction in microglia.272 Further investigation in
to LAMTOR4 and the Ragulator complex in the context of PNO exposure is needed to
understand its role in opioid exposure.
Overall, our study found that IUO and PNO oxy exposure alter the proteome of
SVs, impacting the synaptic abilities of these offspring. Taken together, our results
suggest that in utero and postnatal exposure to oxy can alter the proteome of SVs, thus
influencing signaling pathways and potentially increasing the vulnerability of these
offspring to disease in the future.
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CHAPTER THREE
Characterization of the intergenerational impact of in utero and
postnatal oxycodone exposure
Abstract
Prescription opioid abuse during and after pregnancy is a rising public health
concern. While earlier studies have documented that offspring exposed to opioids in utero
have impaired neurodevelopment, a significant knowledge gap remains in comparing the
overall development between offspring exposed in utero and postnatally. Adding a layer
of complexity is the role of heredity in the overall development of these exposed offspring.
To fill in these important knowledge gaps, the current study uses a preclinical rat model
mimicking oxycodone (oxy) exposure in utero (IUO) and postnatally (PNO) to investigate
comparative and intergenerational effects in the two different treatment groups. While
significant phenotypic attributes were observed with the two treatments and across the
two generations, RNA sequencing revealed alterations in the expression of key synaptic
genes in the two exposed groups in both generations. RNA sequencing and postvalidation of genes using RT-PCR highlighted the differential expression of several
neuropeptides associated with the hypocretin system, a system recently implicated in
addiction. Further, behavior studies revealed anxiety-like behaviors and social deficits that
persisted even in the subsequent generations of the two treatment groups. To summarize,
our study for the first time reveals a new line of investigation on the potential risks
associated with oxy use during and after pregnancy, specifically the disruption of
neurodevelopment and intergenerational impact on behavior.
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Introduction
The widespread abuse of prescription opioids and a dramatic increase in the
availability of illicit opioids have created what is commonly referred to as the opioid
epidemic.211 As a particularly vulnerable group, pregnant women are prescribed opioids
such as morphine, buprenorphine, and methadone to alleviate pregnancy and postpartum
pain, all of which have been shown to cross the placenta.212-214 Data collected by the
Centers for Disease Control and Prevention (CDC) from a 2008-2012 study found that
more than a third of reproductive-aged women enrolled in Medicaid (39%) and more than
a quarter of those with private insurance (28%) filled a prescription for an opioid pain
medication each year.292 Additionally, postpartum women, regardless of delivery method
or pain measurement, commonly receive similar amounts of opioids upon discharge from
the hospital.128,293 The lack of standardization in prescribing patterns of these opioids
contributes to a sizable amount of leftover medication, which can lead to nonmedical use
of the prescriptions.129,293 Among the prescription opioids, oxycodone (oxy) has recently
emerged as a serious contender for widespread abuse. A postoperative analgesic, oxy
has been reported in the literature for postpartum pain or caesarian sections in lieu of
morphine drips,230,231 potentially exposing neonates to this powerful opioid.
Several studies219 have been conducted with rodent models to investigate the
detrimental effects of gestational opioid use on neurodevelopment of the offspring, but few
of these studies consider oxy. Additionally, these prior studies relied on self-administration
or continuous release pumps for drug administration, and very few have used oral delivery
to mimic the usual route of administering pain medication. Orally-administered analgesics
are the most common form of pain relief prescribed after caesarian sections, 294,295 and oral
oxy administration has been shown to be safer than and as effective as intravenous
administration of other opioids.230,296,297 Previous oxy studies have shown deficits such as
behavioral impairments and disruption in both OPRM1 and endothelin receptor expression
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during development in offspring exposed to oxy in utero.180,182-184 However, these studies
focused primarily on prenatal oxy exposure, leaving a large gap in the knowledge
regarding postnatal oxy exposure.
Opiates have been shown to pass into the placenta and act on fetal opioid
receptors.212-214 Opioids also accumulate in the breastmilk.298 The degree of exposure of
an infant to a drug passed through the breastmilk depends on the concentration of the
drug in the milk, the amount of milk ingested, and the rate of elimination from the infant. 232
A human study by Seaton et al. showed that oxy is concentrated in the breastmilk, and
offspring exposed via the breastmilk may receive less than 10% of a typical oral
therapeutic infant dose (0.1–0.2 mg/kg).233 Despite this low dose, infant exposure to oxy
via the breastmilk has been associated with sedation, central nervous system depression,
and neonatal toxicity,234,299-301 and a number of animal studies have also revealed deficits
in behavior and development associated with perinatal opioid exposure.180,182,183,224 The
full extent of postnatal oxy exposure effects is not yet known particularly in regard to
central neural synaptic function and gene expression. Further, pre- and postnatal opioid
abuse can result in several phenotypic consequences across multiple generations of
offspring, despite no previous exposure to drugs.302 Currently, a gap in knowledge exists
regarding the long-term, intergenerational effects of oxy exposure during the perinatal
period on future generations.
The present study was performed to determine the intergenerational effects of in
utero and postnatal oxy exposure on development in both the F1 and F2 generations. This
study was conducted using a Sprague Dawley rat model our labs have previously
established.185 This model consists of two groups of pregnant F0 dams that had been
orally administered oxy. The first group was treated daily with an oral administration of oxy
before, during, and after pregnancy, thereby exposing the F1 pups to oxy in utero (IUO)
throughout fetal and postnatal development. The second group was treated daily with an
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oral administration of oxy only after giving birth, exposing the F1 pups to oxy postnatally
(PNO). The F2 generation was descended from the germlines of F1 dams exposed to oxy
via the breastmilk or in utero, allowing us to elucidate intergenerational effects.
Importantly, both the PNO and IUO groups are clinically relevant.185 The IUO dams
represent women who exhibit chronic opioid use before, during, and after pregnancy, and
the PNO group represents children exposed to opioids after their mothers are prescribed
medication post-caesarian section. Additionally, the PNO group represents neonates in
the neonatal intensive care unit (NICU) that may be exposed to high-dose opiates through
infusions. Infants born with heart defects and persistent pulmonary hypertension are
exposed to opiates for sedation and analgesia while being supported by extracorporeal
membrane oxygenation (ECMO) and mechanical ventilation.227 Infants may be supported
by ECMO for three weeks or longer, exposing the newborns to potent opiates for an
extended period of time and contributing to the increase in diagnoses of neonatal
abstinence syndrome.228,229 Little is known regarding the implications of these opiate drips
and how they may impact neurodevelopment in newborns. Our PNO group provides a
high-dose opiate exposure to the pups that is comparable to the high-dose opiate
exposure neonates in the NICU experience, establishing clinical relevance for the
inclusion of this group in future studies.
The present study uses a holistic integrated systems biology approach to
determine the intergenerational effects of pre- and postnatal oxy exposure on
development in both the F1 and F2 generations descended from oxy-exposed mothers.
Our overall hypothesis was that F0 maternal oxy use and F1 in utero and postnatal oxy
exposure result in developmental impairments (physical, molecular, behavioral) in the F1
offspring that persist in the F2 generation. The comprehensive and systematic approach
used in this study allows for thorough research into intergenerational effects of pre- and
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postnatal oxy abuse, a critical step in closing the knowledge gap surrounding this
commonly used opioid analgesic.

Results
Oxy induces intergenerational developmental differences in exposed pups
To determine whether oxy exposure affects physical development in the PNO and
IUO pups, we measured head size, body weight, and body length on postnatal days (P)
1, 7, 14, and 30 in both generations (Figure 18). Additionally, we calculated the BMI and
LOI to estimate obesity and body fat, respectively (Figure 19). By measuring at these time
points, we can assess perinatal development through periadolescence.303 Additionally,
these time points correspond with human aging from infant, young child, childhood, and
preadolescence.304
At P1 in the F1 animals, PNO pups weighed less than controls. While there were
no differences in F1 weights at P7, a dramatic decline was observed in both PNO and IUO
groups at P14 that persisted through P30. Interestingly, F2 PNO and IUO animals showed
a significant increase in body weights compared to the saline controls at each time point
(Figure 18A). While no significant changes in body length were seen in the F1 pups at P1,
P7, and P14, there was a marked reduction in the body length at P30. In the F2 pups, the
PNO offspring had longer body lengths than both the saline and IUO groups at P1 and
longer body lengths than controls at P14 (Figure 18B). Head size circumference was
markedly affected in the F1 and F2 IUO offspring at birth while F2 PNO pups had larger
head size circumference than both IUO and controls at P1 (Figure 18C).
BMI and LOI measurements were significantly different in the oxy-exposed groups
of both generations. The F1 PNO group had both lower BMI (Figure 19A) and a lower
score on the LOI (Figure 19B) than the saline and IUO groups at P1, suggesting this group
may be underweight. Intriguingly, in the F2 animals, both the BMI (Figure 19A) and LOI
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(Figure 19B) indicated obesity and greater body fat in the IUO at P1. Additionally, while
there were no differences in BMI in the F1 P7 animals, the F2 PNO and IUO groups had
larger BMI than the controls at P7, indicating obesity (Figure 19A). At P14, F1 PNO had a
lower BMI than the saline controls while F2 IUO had a larger BMI than PNO (Figure 19A).
We did not observe any differences in BMI (Figure 19A) in either generation at P30.
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Figure 18. Phenotypic measurements. A-C) Alterations in physical development patterns
in both the IUO and PNO offspring as observed through body weight, body length, and
head size circumference. *p < 0.05; ***p < 0.001; ****p < 0.0001 as determined by TwoWay ANOVA followed by a post-hoc Tukey’s test.
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Figure 19. Phenotypic measurements. Alterations in physical development patterns in
both the IUO and PNO offspring as observed through body mass index (BMI; A) and Lee’s
Obesity Index (LOI; B). *p < 0.05; **p < 0.01; ****p < 0.0001 as determined by Two-Way
ANOVA followed by a post-hoc Tukey’s test.
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RNA-seq identified distinct gene signatures and molecular pathways in the two
generations
Based on the significant physical attributes observed at P14 in the F1 and F2
generations, we performed RNA-Seq analysis on the nucleus accumbens (NAc). The NAc
was chosen given its association with the reward pathway. RNA-Seq analysis showed
several up- and down-regulated genes among the IUO, PNO, and saline groups in both
the F1 and F2 generations. Using Clue-GO analysis (Figure 20), we found that pathways
involved in the regulation of neurological system process, forebrain and neural crest
development, and synaptic transmission were affected by the differentially expressed
genes in the F1 animals. In the F2 animals, we identified pathways involved in fear
response, neurodevelopment, cell signaling, digestive processes, and heart rate
regulation that were affected by the differentially expressed genes. Further, when
comparing the same F1 group comparisons with the F2 comparisons, we found that a
number of genes were consistently differentially regulated in both generations (Figure
21A). Of the differentially regulated genes in both the F1 and F2 generations of saline
compared to IUO, 23 genes were common. For saline compared to PNO, 15 genes were
commonly differentially regulated between the generations. Lastly, when comparing PNO
and IUO, 10 genes were consistently differentially regulated in the F1 and F2 generations.
Potential hits based on a fold change value of ±1.5 that were involved in behavior
and development were selected for post-validation using RT-PCR; we found six genes
successfully post-validated in the F1 and F2 generation (Figure 21B). Interestingly, of the
genes that were post-validated in both F1 and F2, Pmch, Hcrt, and Avp were significant
in both generations. Hcrt and Avp also had similar expression trends among the
experimental groups in both F1 and F2. Intriguingly, the F1 IUO had significantly higher
expression of Pmch compared to both groups, while the PNO had significantly higher
expression in the same F2 comparison. These three genes are important in behavior and
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development and, based on their differential expression, may contribute to the differences
observed between the F1 and F2 offspring.
Because the hypocretin (Hcrt) expression trends were the same in both
generations, we sought to further investigate this system (Figure 21C). We found that
Hcrtr1 expression was significantly higher in the IUO group in both generations. Nptx2, a
protein expressed in orexin neurons, was also highly expressed in IUO compared to PNO
and controls in both generations. In the F1 generation, the PNO also high a higher
expression of Nptx2 compared to controls. Further, Pdyn, the precursor for dynorphin (an
inhibitory neuropeptide co-released with hypocretin), showed higher expression levels in
IUO than both PNO and controls in the F1 generation; both IUO and PNO offspring had
higher levels of Pdyn than controls in the F2 generation.
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Figure 20. RNA-seq analysis on P14 Nucleus Accumbens (NAc) of F1 and F2 animals.
A) Clue-Go pie charts depicting affected biological processes in F1 generations resulting
from differential gene expression between groups. B) Clue-Go pie charts depicting
affected biological processes in F2 generations resulting from differential gene expression
between groups. Results are shown as the percent of genes per group. Asterisks
represent the group term p-value of each category. **p < 0.001.
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Figure 21. RNA-seq analysis on P14 Nucleus Accumbens (NAc) of F1 and F2 animals.
A) Venn diagram depicting the total number of genes affected in the comparison of
treatment groups of each generation. B) Of the genes post-validated in the F1 NAc
samples, Pmch, Hcrt, Otp, Avp, Cdh1, Oxt, and Tcf7l2 were significant. Of the genes postvalidated in the F2 NAc samples, Pmch, Hcrt, Hba1, Avp, Aqp1, and Agrp were significant.
*p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001 as determined by One-Way ANOVA
followed by a post-hoc Tukey’s test. C) Further investigation of the hypocretin system
neuropeptide expression levels found Hcrtr1, Nptx2, and Pdyn were upregulated in the
IUO group of both generations. *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001 as
determined by Two-Way ANOVA followed by a post-hoc Tukey’s test.
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Behavioral deficits continue in the next generation of oxy-exposed pups
Early life insults can significantly impact developmental and behavioral outcomes
exhibited during adulthood. Based on our RNA-seq data that highlighted several genes
associated with behavioral responses, we examined if oxy exposure induces
intergenerational behavioral deficits during adulthood in both IUO and PNO pups.
Accordingly, we performed social interaction and marble burying tests in adult animals
(P60-70).
In the F1 generation, social novelty tests revealed no significant differences in
social interactions of the PNO and IUO groups (Figure 22). However, in the F2 generation,
IUO offspring spent more time with the cagemate than the PNO group and less time with
the naïve animal than both the control and PNO groups (Figure 23A). Although not
significant, the IUO demonstrated a higher tendency to enter the cagemate chamber than
the other two groups (Figure 23A). Additionally, when considering the number of contacts
with the naïve animal, the IUO displayed fewer contacts with the naïve animal (Figure
23A), suggesting a social deficit and hesitancy to spend more time with or interact with the
unknown animal. Similar to the F1 social novelty test results, F1 social preference tests
revealed no significant differences in social interactions exhibited by the PNO and IUO
groups (Figure 22). In the F2 social preference task, IUO animals spent less time with the
naïve animal than did either of the other groups (Figure 23B), and IUO had more contacts
with the toy than had either the PNO or control animals, further suggesting social deficits
in the F2 generation.
Marble burying tests, which measure repetitive stereotypy, compulsive behaviors,
and anxiety-like behavior,305 showed that both the PNO and IUO groups in both
generations buried more marbles than the controls, suggesting heightened anxiety and
compulsivity in these animals (Figure 23C). Interestingly, IUO animals in the F2 group
buried more marbles than the PNO, suggesting that the F1 IUO exposure may result in
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more pronounced intergenerational anxiety and compulsive behaviors than F1 PNO
exposure. In summary, in utero and postnatal oxy exposure can significantly alter
behavioral outcomes that persist into the next generation.
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Figure 22. Social novelty and preference results for F1 animals. A) During the social
novelty test, F1 animals in each group had no significant differences in time spent in each
chamber, number of chamber entries, or number of contacts with the naïve or cagemate
animals. B) During the social preference test, F1 animals in each group had no significant
differences in time spent in each chamber, number of chamber entries, or number of
contacts with the naïve animal or toy.
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Figure 23. F2 Social behavior tests and F1-F2 marble burying. A) F2 social novelty testing
revealed that IUO offspring spent less time with naïve animals and more time with the
cagemate than the other groups. IUO also had fewer contacts with the naïve animal. B)
F2 social preference testing showed IUO spent less time with the naïve animal than the
other groups, and IUO had more contacts with the toy than did the other groups. *p < 0.05,
**p < 0.01, ***p < 0.001 as determined by Two-Way ANOVA followed by a post-hoc
Tukey’s test. C) Marble burying tests in both generations showed increased burying
activity in the PNO and IUO groups. **p < 0.01, ***p < 0.001, ****p < 0.0001 as determined
by Two-Way ANOVA followed by a post-hoc Tukey’s test.
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Discussion
The model system and dose of oxy (15 mg/kg) used in our study mimicked a
chronic prescription opiate-dependent woman during gestation and parturition. This dose
has been shown to be well-tolerated in animals and mimic development of chronic
analgesia in human subjects experiencing breakthrough pain.225,226 A gap in knowledge
exists regarding the implications of how perinatal oxy exposure may impact
neurodevelopment

in newborns

and

affect

long-term

adult

behaviors

in

an

intergenerational manner. Intergenerational transmission of traits and phenotypes results
from direct exposure of the F0 parent and F1 offspring to a stressor,306 such as oxy. When
the oxy exposure occurs in utero, as in the IUO group, the F1 fetus and its germlines are
directly exposed. Additionally, when exposed via the breastmilk, which occurs in both the
PNO and IUO groups, the germlines are also exposed. The exposure of the germline
within the F1 offspring results in an intergenerational transmission to the F2 generation.
Studying the intergenerational effects of oxy exposure in utero and postnatally can
highlight the long-term adverse consequences that extend beyond the mother into future
generations.
Opioid use during pregnancy has been associated with smaller head sizes, lighter
birthweights, and shorter body lengths in newborns.133-137 Our data dovetail with this trend,
showing that in utero oxy exposure affects birthweight, body length, and head
development. A rat study using prenatal exposure to morphine yielded similar results, with
offspring during the preweaning period having a lower body weight as well as a reduction
in brain and cerebellar weights and widths.307 Similarly, a study using buprenorphine
showed delayed offspring development, decreased body weight, decreased body length,
and lower pain sensitivity.308 In our F1 generation, body length appeared to be delayed at
P30 when compared to controls. Interestingly, the F2 PNO pups, specifically, had longer
bodies at P1 and P14, but all F2 body lengths were comparable at P30. As for head size,
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decreased head size and body weight have been reported in a study of NICU neonates.309
In our study, IUO head size circumference in both generations was smaller compared to
controls at P1; head size circumference was comparable to controls at the remaining time
points, however.
With regard to weight, in utero morphine exposure has also been shown to produce
weight deficits that persisted in rats through adulthood,310 much like what we observed in
the F1 PNO and IUO groups. Eriksson et al. showed that rats exposed to prenatal
morphine treatment not only had lower birthweights than controls but also gained less
weight than controls until P19.311 In our study, F1 PNO and IUO pups appeared to maintain
the weight deficit through P30 and did not approach weight levels comparable to saline
controls. Our study also identified differences in BMI and LOI during early development.
Intriguingly, IUO and PNO in the F2 generation had heavier body weights at all time points
compared to controls. Additionally, while the F1 generation trended toward lower BMIs
early in development, the F2 generation had higher BMI scores. In other studies
considering underweight mothers and the weight gain of their offspring, maternal
undernutrition improves the metabolic health of the next generation312 and can lead to
weight gain and obesity in the next generation,313 much like what we observed in our
overweight F2 generation compared to their underweight F1 mothers.
After post-validation of our RNA-seq results, the upregulation of Hcrt in the IUO
groups of both generations led us to investigate the expression of key genes in the
hypocretin system. Hypocretins are involved in arousal, but they are also involved in drug
addiction and reward-related behaviors.314 Hypocretin activation of Hcrtr1 is critical for
morphine withdrawal, and NAc activation during withdrawal is dependent on Hcrtr1
function.315 Not only do our data show an increase in Hcrt expression in IUO pups of both
generations, which is associated with acute opiate withdrawal,316,317 but the expression of
Hcrtr1 in the NAc is also increased significantly in the IUO, further suggesting these IUO
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pups may be experiencing acute withdrawal. Additionally, Nptx2, which regulates the
clustering of AMPA receptors at the synapse, has been shown to increase following opiate
withdrawal.318 The IUO animals in both generations exhibited an increase in Nptx2
expression, again suggesting withdrawal in these animals. Lastly, our IUO animals had
higher levels of Pdyn expression in both generations. Chronic exposure to drugs of abuse
results in the upregulation of the dynorphin (Dyn)/KOR system, and this system has been
shown to contribute to psychiatric disorders such as anxiety, depression, and
addiction.319,320
In addition to highlighting the hypocretin system, our RNA-seq data also
highlighted several genes associated with behavioral responses; therefore we sought to
investigate the impact of IUO and PNO exposure on social behaviors. In human studies,
prenatal opioid exposure has been associated with increased social problems and
difficulty with sociability.309,321 In our social novelty and preference tasks, we did not
observe any significant differences in social behaviors among the F1 groups; however,
the F2 IUO group appeared to exhibit deficits in social interaction behaviors. In the
literature, conflicting results exist regarding the impact of in utero and postnatal opioid
exposure on social behaviors in animal models. In one study of prenatal exposure to
buprenorphine, methadone, and morphine, social interactions in exposed rats were
impaired, similar to what has been reported in human studies.322 In contrast, other studies
have shown that prenatal morphine exposure increased social behaviors and resulted in
less social avoidance.323,324 Differences in results may be due to different experimental
designs, such as behavior chambers and scoring or the dosing schedule of the animals.
For example, many reported behavioral tests for prenatal opioid exposure studies have
tested social interaction and play behavior in open chambers where the animals can
interact freely.322-324 Our social preference and novelty tests used a three-chambered
apparatus that did not allow for free interaction or play between the test rat and the
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cagemate or naïve animal. As for treatment differences, both Hol et al. and Niesink et al.
treated rats with morphine during the last week of gestation and showed increased play
behavior in the offspring.323,324 Najam and Panksepp, however, showed that early
postnatal treatment causes a delay in achieving control levels of play behavior in rats.325
Our treatment paradigms started prior to mating and continued until weaning (IUO) or
started only after giving birth and continued until weaning (PNO). Alterations in rodent
behavior post-treatment may depend on the stage of development at which the offspring
are exposed to treatment, and social problems resulting from intrauterine309 or
adolescent303 exposure may resolve with age. Our social behavioral tests occurred during
young adulthood (P60-65), so perhaps any existing social deficits returned to baseline by
the time of testing. The antisocial behavior exhibited by the F2 IUO animals may be
attributed to the downregulation of Avp highlighted in our NAc RNA-seq and postvalidation data. AVP systems have been shown to modulate social behaviors in rats,326
and blocking AVP receptors resulted in significantly decreased investigation of novel
objects.327 Therefore, the regulation of Avp and its effects on social behavior in the context
of perinatal opioid exposure may be an important avenue of study for future work.
In addition to social behaviors, we investigated compulsive and anxiety-like
behaviors using marble burying tests in both generations. In our study, both the PNO and
IUO groups in F1 buried more marbles than the control group, suggesting the presence of
anxiety-like and obsessive-compulsive phenotypes. This pattern persisted into the F2
generation, demonstrating intergenerational effects of maternal opioid exposure on
subsequent generations. Importantly, the hypocretin system has been implicated in
anxiety disorders.328 Hcrtr1 antagonists have been shown to attenuate anxiety-like
behaviors.329 Further, Hcrtr1 activity is anxiogenic, while Hcrtr2 activity is anxiolytic. 330 The
increased expression of Hcrt and Hcrtr1 may contribute to the anxiety-like behaviors
exhibited by both generations. Further, prenatal exposure to morphine and methadone
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has been shown to increase anxiety-like behaviors in light-dark transition and elevated
plus-maze tests in both male and female rats.322 Additionally, Rohbani et al. found that
parental morphine exposure affected compulsive grooming and anxiety-like behaviors
through marble burying in the offspring.331 In the case of the F2 IUO, the F1 germ line that
would produce F2 was directly exposed, contributing to the intergenerational effect we
saw on anxiety-like behavior in this group. In a study using marble burying to assess
autism-like and anxiety-like behaviors, increased marble burying occurred in F1, F2, and
F3, suggesting that these behaviors may exist through transgenerational epigenetic
inheritance.332 Our F2 animals exhibited the same anxiety-like behaviors as the F1
animals; thus, extension of this study to F3 may elucidate whether transgenerational
inheritance is involved in this behavioral phenotype. It is important to note that, while the
number of marbles buried in the F1 oxy-exposed groups was roughly similar, the F2 IUO
buried significantly more marbles than the F2 PNO, suggesting the IUO may be the more
severely impacted of the two groups.
Overall, our study is the first to identify intergenerational effects of pre- and
postnatal oxy exposure on development and behavior, thus prompting caution, as both
routes of exposure can lead to developmental deficiencies that may persist into the next
generation.
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DISCUSSION AND FUTURE DIRECTIONS
Discussion
The findings reported in this thesis are novel and contribute greatly to the field of
perinatal opioid exposure. By using the Sprague Dawley rat model to mimic oxy exposure
in utero and postnatally, we have elucidated lasting developmental, biochemical,
molecular, and behavioral alterations in exposed progeny. The findings reported for the
F1 generation of oxy-exposed offspring as well as the intergenerational impacts of oxy
exposure described in these results provide a sufficient baseline upon which future
transgenerational studies may build to further investigate physical development, synaptic
alterations, behavior, neurological disease, neuroinflammation, and more.
Within the F1 generation itself, oxy exposure had several developmental impacts.
Much like what has been observed in other studies of prenatal opioid exposure,310,311 both
the PNO and IUO groups had lower body weights and shorter body lengths than controls.
The IUO were also born with smaller head size circumferences than either PNO or control
pups. A possible factor impacting head size circumference may be the metabolite TAU;
IUO pups had lower TAU levels than either PNO or control animals. Interestingly,
Hernandez-Benitez et al. have shown that TAU promotes neural development in the
embryonic brain as well as in adult brain regions,244 so it may be that this deficit in TAU
impacted the development of the brain and contributed to the smaller head size
circumference of P1 IUO pups. Further, as the IUO pups aged, we found that TAU levels
increased, which coincided with the return of head size circumference measurements to
a comparable size with control and PNO offspring at P30. To further explore this
possibility, future studies should aim to investigate TAU levels of P1 pups to discover
whether the TAU deficiency is present from birth to P14, or whether it develops during the
first two weeks of postnatal development.
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Through electrophysiology, RNA-seq, and SVs, our studies of the F1 generation
of oxy-exposed animals have demonstrated alterations in synaptic abilities of these
offspring. Glutamate receptors have a role in mediating the reward pathway, particularly
AMPA receptors, which are crucial for opioid withdrawal during development.249-254 Our
studies suggest altered AMPA subunit composition in the P14 PNO pups but no adverse
effects in the IUO group, possibly due to possible neuronal loss due to longer oxy exposure
and increased GLU levels in these pups.255,256 Although no receptor signaling alterations
were identified in the IUO group through electrophysiology, we found that Nptx2
expression in the NAc was increased in both the IUO and PNO groups at P14. Intriguingly,
Nptx2 regulates the clustering of AMPA receptors at the synapse and has been implicated
in withdrawal.318 Nptx2 has been consistently associated with AMPA-mediated excitatory
synaptogenesis;333 therefore, as P14 is the peak of synaptogenesis in rats, it may be
interesting to further evaluate synaptogenesis and the role of AMPA receptors and Nptx2
in the PNO and IUO offspring during early development, particularly in the PNO offspring
that may have altered AMPA subunit composition according to our electrophysiology
results. Further synaptic alterations were revealed through our RNA-seq studies of both
the PFC and the NAc of IUO and PNO animals. These studies showed alterations in genes
associated with pathways involved in synaptic transmission, axon guidance,
inflammasomes, and the reward system. Chronic oxy exposure has previously been
shown to contribute to axonal degeneration as well as alter white matter through
deformation of axonal tracks, reduced axonal fascicle size, loss of myelin basic protein,
and the accumulation of amyloid precursor protein.224 Intriguingly, loss of MEGF8, which
was downregulated in the P14 IUO SVs, disrupts axon guidance in the peripheral nervous
system.287 As human studies of infants exposed to opioids prenatally have shown punctate
white matter lesions and white matter signal abnormalities in structural MR imaging, 263,264
further investigation of MEGF8 loss in the IUO group would be interesting to elucidate any
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lasting effects of IUO exposure into adulthood. Additionally, investigating the axonal
structure of P14 IUO brains would also be an intriguing follow-up study to relate our SV
data showing MEGF8 downregulation and our RNA-seq data suggesting axon guidance
pathway alterations.
An interesting aspect of our F1 studies revealed an enrichment of the sensory pain
pathway as well as a lower pain threshold in IUO and PNO animals in adulthood (P75).
This lowered pain threshold may be the result of opioid-induced hyperalgesia (OIH), a
state of nociceptive sensitization caused by exposure to opioids.334 Increased
hyperalgesia has been reported previously in prenatal opioid exposure studies and, as
reported from studies using cross-fostering at birth, may be due to effects incurred during
gestational exposure to opioids.219 The molecular mechanisms of OIH are not well
understood,334 but the involvement of the central glutaminergic system and dynorphins are
particularly interesting in the context of our study. NMDA receptors have been shown to
play a large role in OIH; inhibiting NMDA receptors with antagonist MK-801 blocked
morphine tolerance and thermal hyperalgesia.335 Further, hyperalgesia has been
associated with alterations in subunit composition of AMPA receptors.336 Fittingly, our P17
electrophysiological studies revealed alterations in AMPA subunit composition in PNO
rats. As the P17 rats did not demonstrate any differences in pain thresholds, it may be
interesting to extend our electrophysiological studies to P75 to further investigate AMPA
and NMDA receptor function in the context of OIH in the IUO and PNO animals. As for
dynorphins and OIH, spinal dynorphins have been shown to increase with continuous
infusions of µ-receptor agonists.337 Interestingly, prodynorphin, the precursor to dynorphin,
was increased in the F1 IUO animals at P14. Notably, LAMTOR4, which was upregulated
in the SVs of our P14 PNO animals, may also influence OIH through its role in the
Ragulator complex, which controls the activity of mTORC1. mTORC1 is required for the
initiation and maintenance of chronic pain and OIH.290 As LAMTOR4 was only upregulated
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in the PNO group at P14, it would be advantageous to further investigate mTORC1 and
LAMTOR4 in both PNO and IUO groups at P75 to not only establish whether the
differential expression of LAMTOR4 in PNO still exists, and if so, whether it exists outside
of SVs, but also to discern whether the hyperalgesia found in our Von Frey study is
dependent on mTORC1.
When considered together, the 1H-MRS and RNA-seq studies used in our research
provided insight into the susceptibility of the F1 generation to future diseases and mental
disorders. In the PFC RNA-seq data from the F1 generation, we found that genes
associated with depression, anxiety, schizophrenia, and obsessive compulsive disorder
were enriched in both PNO and IUO offspring. Interestingly, in our marble burying study,
F1 IUO and PNO buried more marbles than controls, indicating heightened anxiety and
compulsive behavior. A large number of genes associated with renal diseases were also
highlighted. Further, the depletion of TAU in our IUO group may further impact possible
renal dysfunction.243 It is also worth noting that, although not significant, the trend of higher
CRE and MYO levels in the F1 P17 IUO offspring may indicate gliosis in these animals.338
Reactive gliosis, or neuroinflammation, involves the accumulation of microglia and
astrocytes immediately following the occurrence of a CNS injury.339 Interestingly, elevated
levels of CRE and increased gliosis have been identified in studies of multiple
sclerosis.340,341 Also within the realm of gliosis, LAMTOR4, which was upregulated in the
SVs of our P14 PNO animals, is essential for microglia development; improper LAMTOR4
and Ragulator function lead to abnormal lysosomal accumulation within the microglia,
rendering the microglia incapable of digesting debris that may contribute to neurological
diseases such as Alzheimer’s disease.272 Interestingly, studies have reported higher MYO
levels in patients with Alzheimer’s disease and dementia.342-344 Further, several genes
associated with Alzheimer’s disease (Psen1, Chrnb2, Dpysl2, Amfr, Pcdh1x, Npy, Bcl2)
were also highlighted in the IUO and PNO groups in the bioinformatic analysis of our PFC
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RNA-seq data. Furthermore, the IPA of our SV contents suggested an increase in CRE in
the IUO pups as well as highlighted neurological disease as a top hit in both IUO and PNO
groups; however, in our 1H-MRS study of P30 IUO, CRE and MYO levels were lower than
controls. More investigation is needed to determine whether gliosis during P14 is
increased, how an upregulation in LAMTOR4 affects gliosis in the PNO offspring, and
whether an increase in gliosis during early development has any lasting effects into
adulthood in the IUO offspring, including any impact on the expression of genes related to
Alzheimer’s disease.
Although not investigated as thoroughly as the F1 generation, the F2 generation
demonstrated the impact of oxy exposure on development, gene expression, and behavior
in an intergenerational manner. Like the F1 generation, F2 IUO P1 pups had smaller head
size circumferences than either PNO or saline pups. In the F1 generation, this smaller
head size circumference may be due in part to the lower levels of TAU, we are unsure
whether this is the case for the F2 generation. Extending the 1H-MRS studies into the F2
generation may offer more insight into the smaller head size circumference of P1 IUO
pups in the F2 generation. In contrast to the F1 generation, the F2 pups in the IUO and
PNO groups weighed significantly more than saline counterparts at P1, P7, P14, and P30.
Further, the P1 F2 IUO offspring had higher BMI and LOI scores than the saline and PNO
offspring, and both oxy-exposed groups had higher BMI scores than saline pups at P7.
Because the F1 mothers were underweight as they approached adulthood, it may be
possible the F2 generation was affected in a compensatory way. Maternal undernutrition
has been shown to improve the metabolic health of the next generation, 312 often leading
to weight gain and obesity in these offspring.313 Future studies may aim to further
investigate this effect by cross-fostering the pups to dams that did not have IUO or PNO
exposure themselves.
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While our intergenerational study did not include studies on synaptic signaling, it
did provide insight into the molecular effects of oxy exposure in the NAc. The most
influential finding from this intergenerational study was the upregulation of Hcrt in the IUO
of both F1 and F2 generations. Hypocretins are involved in drug addiction and rewardrelated behaviors,314 and activation of Hcrtr1 is critical for morphine withdrawal and NAc
activation during withdrawal.315 The increased expression of Hcrt and Hcrtr1, along with
the increased expression of Nptx2, in the IUO pups is associated with acute opiate
withdrawal.316-318 Investigations into withdrawal in the IUO offspring, specifically those in
the F1 generation that are actively exposed to oxy during development, using an opioid
antagonist such as naloxone may allow us to verify addiction and withdrawal through a
behavioral test. Additionally, Pdyn was highly expressed in F1 and F2 IUO animals. As
dynorphins have been associated with OIH,334 and as the F1 oxy-exposed groups appear
to exhibit OIH, extending the Von Frey testing to the F2 generation may yield interesting
insight into the possibility of lasting hyperalgesia effects in the F2 generation. Further
investigation of the hypocretin system and related genes in terms of epigenic modification
would be the next step for this study to determine the extent of these effects and whether
they are inherited from the mother.
The social behavior studies in the F1 and F2 generations provided us with
interesting findings regarding the F2 generation. In human studies, prenatal opioid
exposure has been associated with increased social problems and difficulty with
sociability.309,321 While our F1 animals exhibited no differences in social behaviors, the F2
IUO group demonstrated deficits in social interaction behaviors. Because alterations in
rodent behavior post-treatment may depend on the developmental stage at which the rats
are exposed to treatment, social problems resulting from intrauterine309 or adolescent303
exposure may resolve with age. Our social behavioral tests occurred during young
adulthood (P60-65), so perhaps any existing social deficits in the F1 generation returned
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to baseline by the time of testing. Perhaps implementing different social testing paradigms
or testing at an earlier age may shed more light on any social deficits in the F1 animals.
As for the antisocial behavior exhibited by the F2 IUO animals, the downregulation of Avp
highlighted in our NAc RNA-seq and post-validation data may play a role. AVP systems
have been shown to modulate social behaviors in rats,326 and blocking AVP receptors
resulted in significantly decreased investigation of novel objects.327 As Avp was also
downregulated in the F1 IUO animals, yet these animals showed no social deficits,
studying the AVP system in both generations while also employing different social
behavior paradigms may yield more information on whether this system truly affects social
behavior in these oxy-exposed animals.
As a number of genes associated with anxiety and obsessive-compulsive disorder
were highlighted in the F1 P14 RNA-seq as well as in the F1and F2 P14 NAc RNA-seq,
we employed marble burying tests in both generations to study these behaviors. In our
study, both the PNO and IUO groups in both F1 and F2 generations buried more marbles
than the control group, suggesting the presence of anxiety-like and obsessive-compulsive
phenotypes that may be inherited intergenerationally. Importantly, the hypocretin system
has been implicated in anxiety disorders.328 Hcrtr1 antagonists have been shown to
attenuate anxiety-like behaviors.329 Further, Hcrtr1 activity is anxiogenic, while Hcrtr2
activity is anxiolytic.330 The increased expression of Hcrt and Hcrtr1 may contribute to the
anxiety-like behaviors exhibited by both generations. In addition to the hypocretin system,
Abraham et al. suggest the involvement of KOR; activation of KOR with agonist U50488
significantly increased the number of marbles buried, suggesting KOR-mediated
increases in anxiety-like or stress-induced compulsive behaviors.345 Additionally, chronic
exposure to drugs of abuse results in the upregulation of the Dyn/KOR system, and this
system has been shown to contribute to psychiatric disorders such as anxiety, depression,
and addiction.319,320 Importantly, from our NAc RNA-seq data of F1 and F2 generations,
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we do see an upregulation of Pdyn expression in the oxy-exposed groups. Further,
prenatal exposure to morphine and methadone has been shown to increase anxiety-like
behaviors.322 Parental morphine exposure has also been shown to affect compulsive
grooming and anxiety-like behaviors in the offspring.331 In a study using marble burying to
assess autism-like and anxiety-like behaviors, increased marble burying occurred in F1,
F2, and F3, suggesting that these behaviors may exist through transgenerational
epigenetic inheritance.332 Our F2 animals exhibited the same anxiety-like behaviors as the
F1 animals; thus, extension of this study to F3 may elucidate whether transgenerational
inheritance is involved in this behavioral phenotype.
Based on the findings of our intergenerational study of IUO and PNO exposure
groups in which we identified the differential expression of key genes involved in the
hypocretin system as well as physical and behavioral effects of oxy exposure, the
extension of this study to a transgenerational model is critical. Moreover, performing
electrophysiology, 1H-MRS, SV isolation and characterization, and pain testing would be
advantageous in further defining intergenerational effects of oxy exposure in the F2 IUO
and PNO groups. As the findings in our intergenerational study regarding the F1
generation may provide more insight into those studies performed solely in the F1
generation, so too may we extend the F1 studies into the F2 generation to further explore
these changes. The study of the generational impact of oxy exposure may be
strengthened by the investigation of transgenerational effects and any possible epigenetic
alterations that contribute to the generational inheritance of phenotypic, molecular, or
behavioral alterations exhibited by the IUO and PNO offspring.

Future Directions
Although we employed a comprehensive approach in investigating the effects of
pre- and post-natal oxy exposure, there are several ways in which our studies can improve
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in the future. Our approach focused on the maternal effects of oxy use. However, a
growing body of research considers the paternal effects of opioid use on the offspring.
Paternal use of opioids such as morphine and heroin have been shown to have sexspecific effects on object recognition memory,167 increased anxiety and aggression,172 and
altered pain perception and signaling.152,153 As our study has shown that pre- and postnatal exposure to oxy via the mother have led to developmental, behavioral, and molecular
alterations, extending our study to include a parental exposure group may also lend critical
insight into intergenerational inheritance of these alterations. Additionally, our studies may
also benefit from monitoring maternal behavior and nutritional intake to determine the type
of environment and nutrition the pups had in the three different conditions. The weight
deficits reported in the F1 IUO and PNO groups may be the result of altered maternal care
or nutritional intake. Morphine exposure has been shown to disrupt maternal behavior, 346
and proper nutritional status of the mother may be impacted by substance use, thus
impacting the breastfeeding offspring.347,348 By investigating maternal effects as well as
nutrition, we can better understand the consistent weight deficits exhibited by the F1 oxyexposed animals. Further, because maternal undernutrition may improve the metabolic
health of the next generation312 and lead to weight gain and obesity in the next
generation,313 understanding the persistently low weights of the F1 generation may
provide more information relevant to the overweight F2 generation.
Another important aspect to include in future studies regarding the mother would
be the establishment of addiction. Without testing withdrawal, our groups cannot be
defined as “addicted” but instead are referred to as “exposed.” Although our studies were
conducted in the context of oxy exposure, it may be beneficial to extend our study to cover
addiction as well. Using a naloxone treatment on the dams and monitoring behavior would
allow us to discern whether our dosing regimen is sufficient to establish addiction. In the
case of exposed offspring, determining the concentration of oxy in the breastmilk would
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be important in understanding exposure versus addiction in the pups. Once we determine
the amount of oxy pups receive, withdrawal in the pups can be measured at weaning with
a naloxone treatment and subsequent monitoring of withdrawal behaviors, allowing us to
consider our findings in the context of addiction rather than exposure.
Perhaps the most prominent finding from our study that warrants further
investigation is the role of the hypocretin pathway in the intergenerational effects of
perinatal oxy exposure. Because of its role in the regulation of motivation, arousal, and
stress, the hypocretin system has become a promising target for the treatment of
substance use disorder. Hypocretins, also known as orexins, are neuropeptides derived
primarily from hypocretin-containing neurons in the lateral hypothalamus. Hypocretin-1
(orexin-A) and hypocretin-2 (orexin-B) act through hypocretin receptor types 1 (Hcrtr-1, or
OX1R) and 2 (Hcrtr-2, or OX2R), respectively, and have a number of physiological roles,
such as the regulation of the sleep-wake cycle, feeding behavior, energy homeostasis,
and reward-seeking.349 Hypocretin signaling dysfunction has been associated with
narcolepsy, insomnia, depression, stroke, and, importantly, addiction.314,349,350 Studies of
alcohol,351 opioid,352 and cocaine353 use have shown Hcrtr-1 involvement in addictive
behaviors. Because nearly half of all hypocretin neurons express mu-opioid receptors, the
main target of opioids,354,355 targeting the hypocretin system may reduce opioid intake,
craving, and relapse.352 Indeed, recent studies have shown that Hcrtr-1 blockade
attenuates drug-seeking behavior in rat self-administration studies.351,353 Further,
activation of Hcrtr-1 is critical for morphine withdrawal, and the activation of the NAc during
withdrawal is dependent on Hcrtr-1 function.315 Hcrtr-1 antagonism has effectively reduced
motivation for oxy, fentanyl, and remifentanil.352 Recently, suvorexant, an FDA-approved
treatment for insomnia that blocks the activity of both Hcrtr-1 and Hcrtr-2, has been applied
in clinical trials356,357 for the treatment of sleep, craving, and stress states in patients with
substance use disorders, including opioid use disorder; however, no data are published
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yet. Because we have identified an upregulation of the hypocretin system in both the F1
and F2 generations of oxy-exposed pups, the addition of a treatment with an Hcrtr-1
antagonist, such as suvorexant, may mitigate this upregulation. This would be particularly
interesting if our studies also extended into the susceptibility of the IUO and PNO offspring
to future drug use and addictive behaviors. To best explore the impact of hypocretin
system upregulation with PNO and IUO exposure may require the use of a selfadministration study. Extending our intergenerational study to include a self-administration
model of oxy addiction for the adult F1 and F2 pups would allow us to study any
predispositions to oxy addiction, withdrawal, and, by using an Hcrtr-1 antagonist, further
investigate how the upregulation of the hypocretin system and the blocking of Hcrtr-1
impact addiction and withdrawal in these oxy-exposed animals.
As Hcrtr-1 antagonists like suvorexant are only recently being investigated as
potential therapeutics for opioid use disorder, it may be interesting to consider the effects
of other therapeutic interventions for maternal opioid use on our IUO and PNO groups.
Methadone, a synthetically derived agonist that binds to mu-, kappa-, and delta-opioid
receptors, exerts morphine-like effects and, therefore, is the most commonly used
pharmacotherapy for opioid dependence, including pregnant women.322 Buprenorphine, a
semisynthetic thebaine derivative that selectively binds to the mu-opioid receptor as a
partial agonist, the nociception receptor as a full or partial agonist, and the kappa-opioid
receptor as an antagonist, has also been used to treat opioid dependence during
pregnancy.322 Although used for treatment of opioid use in pregnant women as well as for
infants with NOWS, methadone and buprenorphine are not without their own faults. Animal
studies have shown that buprenorphine and methadone maintenance therapy produce
detrimental side effects on cognitive function and social behaviors322 as well as influence
the severity anxiety-like behaviors.358 Human studies have shown that newborns exposed
to buprenorphine prenatally exhibited mild symptoms of NOWS359 that were not as severe
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as those identified in newborns exposed to high-dose methadone.360 Prenatal methadone
exposure was also associated with weakness in language and cognition.197 Contrarily,
other human studies have revealed no significant differences in neurobehavioral
outcomes between newborns exposed to buprenorphine versus those exposed to
methadone.361 It may therefore be interesting to include a buprenorphine or methadone
treatment group in our IUO and PNO studies to determine how treatment with these drugs
may impact the development of the oxy-exposed pups.
Further, Jantzie et al. have recently shown that perinatal methadone has a distinct
systemic and neuroinflammatory signature.291 Based on these findings, the authors posit
that prenatal opioid exposure may be the next neuroinflammatory disease. Further
investigation into the possible increase in gliosis in the F1 IUO suggested by our 1H-MRS
and RNA-seq studies may allow us to identify whether prenatal oxy exposure can also be
associated with neuroinflammation. By isolating plasma from our IUO groups during the
perinatal period and adulthood and by measuring the concentration of inflammatory
cytokines and chemokines, we could investigate sustained neuroinflammation in these
animals. If prenatal oxy exposure also has distinct neuroinflammatory signatures, perhaps
the use of anti-inflammatory drugs may mitigate the changes our F1 studies have found.
Further, implementing this investigation in the context of inter- or trans-generational
inheritance may also yield more information about the extent of prenatal opioid exposure
as a neonatal inflammatory disease.
Overall, our studies provide a solid groundwork on which future studies can build
to further investigate the generational effects of perinatal oxy exposure. Since we have
characterized maternal oxy use and the effects on F1 and F2 offspring, the addition of
paternal exposure groups would add to our knowledge of the generational effects of oxy
exposure by considered exposure from either parent. The hypocretin pathway is becoming
increasingly relevant as a possible treatment for opioid use, as evidences by ongoing
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clinical trials. The investigation of therapeutics such as buprenorphine, methadone, and
the more recent suvorexant may aid in the identification of the most effective treatment for
opioid-using mothers or newborns diagnosed with NOWs. Investigating prenatal oxy
exposure in the context of a neonatal inflammatory disease would also be a novel and
intriguing possibility for future work. Taken together, the further investigation of each of
these avenues of research would provide us a more complete understanding of perinatal
oxy exposure and the severity of any subsequent generational consequences.
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